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There is recognition that biomedical research into the causes of mental disorders and their
treatment needs to adopt new approaches to research. Novel biomedical techniques have
advanced our understanding of how the brain develops and is shaped by behaviour and
environment. This has led to the advent of stratiﬁed medicine, which translates advances in
basic research by targeting aetiological mechanisms underlying mental disorder. The resulting
increase in diagnostic precision and targeted treatments may provide a window of opportunity to
address the large public health burden, and individual suffering associated with mental disorders.
While mental health and mental disorders have signiﬁcant representation in the “health,
demographic change and wellbeing” challenge identiﬁed in Horizon 2020, the framework7 848 5314.
kcl.ac.uk (G. Schumann).
nvenor for work package sub-groups.
7Medicine for mental disordersprogramme for research and innovation of the European Commission (2014–2020), and in national
funding agencies, clear advice on a potential strategy for mental health research investment is
needed. The development of such a strategy is supported by the EC-funded “Roadmap for Mental
Health Research” (ROAMER) which will provide recommendations for a European mental health
research strategy integrating the areas of biomedicine, psychology, public health well being,
research integration and structuring, and stakeholder participation. Leading experts on
biomedical research on mental disorders have provided an assessment of the state of the art
in core psychopathological domains, including arousal and stress regulation, affect, cognition
social processes, comorbidity and pharmacotherapy. They have identiﬁed major advances and
promising methods and pointed out gaps to be addressed in order to achieve the promise of a
stratiﬁed medicine for mental disorders.
& 2013 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
The worldwide disease burden (DALY) of mental disorders
among non-communicable diseases is 28% (Prince et al.,
2007) and the cost of mental disorders in Europe in 2010 was
€523.3 billion (Gustavsson et al., 2011). This is a severe
public health problem, which requires urgent action. There
is of course recognition of the need for action in this area.
President Obama recently announced BRAIN (Brain Research
through Advancing Innovative Neurotechnologies) and the
EU month of the Brain in May 2013 facilitated discussions on
investments in scientiﬁc excellence as well as strategies to
improve patient beneﬁt and disease prevention. The mental
health disorder challenge has signiﬁcant representation in
the “health, demographic change and wellbeing” challenge
identiﬁed in “Horizon 2020” the framework programme for
research and innovation of the European Commission (2014–
2020) (European Commission, 2013), as well in research
strategies by national funding agencies.
In the scientiﬁc community there is widening recognition
that biomedical research into the causes of mental disorders
and their treatment needs to develop novel paradigms and
improved psychopharmacological targets to reduce the
size and burden of mental disorders in the 21st century.
Recent neurobiological techniques involving neuroimaging,
neuropsychology, neurobiology and -omics (Anon, 2010;
Meyer-Lindenberg, 2010) have tremendously advanced our
understanding of brain development and function, including
our knowledge of how cognition, affect and behaviour
relate to brain circuitry. Based on this progress stratiﬁed
medicine, an approach which uses genetic and/or endophe-
notypic measures to allow more precise diagnostics and
better targeting of treatments (Owen et al., 2013), has
emerged. Stratiﬁed medicine for mental disorders aims to
identify somatic, cognitive, affective, motor and social-
behaviour domains deﬁned by associated, potentially com-
mon, aetiological neural mechanisms (see examples in
Schumann et al., 2010a; Robbins et al., 2012). This is in
contrast to existing diagnostic criteria which are usually
based on patient report, observation and duration of
symptoms and do not incorporate biological or neuropsy-
chological markers (Kapur et al., 2012).
Given that many of the biological and psychological ﬁndings
are present across disorders, exclusive reliance on current
diagnostic classiﬁcation might be an obstacle for improved
aetiological research. It may also hinder the search forimproved future classiﬁcatory principles. Aetiology-based
research cutting across diagnostic boundaries may be a critical
step towards overcoming what some view as “therapeutic
stagnation in psychiatry” and provide patient beneﬁt and
reduce the public health burden. These “transdiagnostic”
strategies need to take into account the close relation of
psychological and biomedical research in basic and clinical
mental health research. They may offer a new and rational
path for the development of a stratiﬁed psychiatry.
A key element is the concerted effort supported by
academic researchers, representatives from pharmaceutical
industry, regulatory authorities (Broich et al., 2011) and
funding bodies to use and expand our knowledge of the
(neuro-)biology of behaviours and functions. The identiﬁca-
tion and validation of translational behavioural and physio-
logical (biomarker) assays, experimental perturbations,
in vitro and in vivo tools, experimental medicine in
volunteers and patients and reverse translation as well as
neuropsychiatric drug discovery are too multifaceted for
any one academic or industrial concern to tackle alone.
They also require a range of modiﬁcations in regulatory
authorities. The European Commission (EC) has recognised
the requirement for more intensive public–private colla-
boration in neuropsychiatric research. EC-funded research
projects also facilitate networks among the private sector,
academia, regulatory, patient-advocacy groups and other
stakeholders. As part of the Innovative Medicines Initiative
Joint Undertaking, the EU is supporting several projects,
which investigate the biological mechanisms of mental
disorders.
To further develop and expand these efforts a strategy
for mental health research investment is required. The
development of such a research strategy is supported by
the EC-funded “Roadmap for Mental Health Research”
(ROAMER, 2013). This project will create an integrated and
participatory roadmap for mental health research in Europe.
It is structured in several work packages, namely ‘Structuring
of research capacity, infrastructures, capacity building &
funding strategies’; ‘Biomedical research’; ‘Psychological
research and treatments’; ‘Social and economic aspects’;
‘Public health research’; ‘Well-being’; ‘Analysis of geographic,
clinical, multi-disciplinary and life course integration’;
‘Stakeholder involvement’; ‘Promotion and dissemination’;
and ‘Translation into Roadmaps’. The ROAMER initiative is
aligned with the Horizon 2020 programme and its three pillars
of excellent science; industrial leadership and
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Proposal for a COUNCIL DECISION. Establishing the Speciﬁc
Programme Implementing Horizon 2020 – The Framework
Programme for Research and Innovation [2014–2020]). It is
highly participatory with involvement of all key stakeholders
(patients, industry, funding organisations and policy makers)
to ensure that its recommendations are socially relevant as
well as scientiﬁcally excellent. All ROAMER work packages
have a similar methodology of a critical appraisal using experts
and state-of-the-art reviews. These suggestions will be con-
sidered by the scientiﬁc community as well as by stakeholder
groups. Their likely costs and chances of impact on mental
health burdens and the European agenda of competitiveness,
growth and jobs will be assessed. The ﬁnal recommendations
will balance the priority levels of each of the identiﬁed
potential gaps in research.
The ROAMER workpackage on “Biomedical Research”
involves biomedical researchers on mental disorders who
have engaged with a group of leading experts to provide an
assessment of the state of the art of biomedical research,
identify major advances and promising methods and point
out gaps that ought to be addressed in future research.
Recognising the constraints of the current diagnostic classi-
ﬁcation systems the members of the workpackage decided
to structure their assessment on behavioural domains
relevant for psychopathology. This strategy is consistent
with similar decisions in the NIMH's Research Domain
Criteria (RDoC) initiative (Insel et al., 2010) and proposes
a two dimensional matrix structure with several “Research
Domains” (and sub-domains), which are selected to provide
comprehensive coverage of human behaviour. The domains
include negative and positive valences, cognitive systems,
systems for social processes, and arousal and regulatory
systems. The second dimension of the matrix is comprised of
“Units of Analysis”, which includes genes molecules, cells,
circuits, physiology, behaviour, self-reports and paradigms.
A similiar approach was used by the workpackage on
“psychological research and treatments”.
Experts were selected by the workpackage members for
their academic excellence and competence in the research
domains and the different units of analysis. Their contribu-
tions are not systematic reviews but rather provide a well-
informed opinion of the authors involved. They do not
represent ofﬁcial ROAMER consortium statements but con-
tribute to the comprehensive and participatory approach of
ROAMER. A description of the methods and the gaps and
advances of the whole ROAMER consortium can be found on
〈http://www.roamer-mh.org/〉. The workpackage on “psy
chological research and treatments” also produced a set of
position statements presenting views and perspectives on
the scope, current topics, strength and gaps in Psychological
Science. These statements aim to delineate advances
needed to inform future research agendas speciﬁcally on
the understanding of psychological (mental), developmental
and neurobiological processes and the psychological treat
ment of maladaptive health behaviours and mental disor
ders (Wittchen et al. 2013).
While RDoC provides a compelling theoretical advantage,
it became evident in the course of the project, that from a
clinical perspective there is an incomplete ﬁt between
behavioural domains on the one hand and psychopathologi-
cal criteria on the other hand. More reﬁned behaviouralcharacterizations may better capture clinically relevant
psychopathology. Further challenges for this framework
are the integration of epidemiological evidence, such as
the importance of environmental inﬂuences and life span
symptoms and a developmental perspective. These are just
some of the conceptual problems necessary to be tackled if
a biologically based classiﬁcation of psychiatric disorders is
to become of clinical signiﬁcance, and of beneﬁt to
patients. Nevertheless, RDoC is a useful framework to focus
our minds on the type of biomedical research necessary to
identify and target speciﬁc biological processes underlying
psychopathology, and to translate it into transformative
clinical studies capable of alleviating the public health
burden posed by mental disorders. At the same time we
acknowledge the continued need to appreciate classical
psychopathology and current diagnostic conventions for diag-
nosing mental disorders, last not least to provide appropriate
linkage to current clinical practice standards and current
knowledge.
2. Arousal and stress regulatory systems
Arousal and stress systems are crucial for adaptation,
resilience and health, but if these systems are dysregulated
the vulnerability to psychiatric disorders is enhanced. In
recent years, it is better understood how the mediators of
these systems can change their action from protective to
harmful. In addition to these novel insights into the action
mechanism, it is also recognised that vulnerability and
resilience are adaptations to the outcome of (adverse)
experiences at critical times during brain development
and maturation. At the root of this notion are newly
discovered mechanisms explaining the interaction of
experience-related factors with genetic and environmental
inputs that underlies emotional expression and cognitive
function for better and for worse. Arousal and stress power
these gene environmental interactions in which the bal-
ance between factors that activate and suppress the
processing of stressful information, respectively, is crucial
for the mechanism of resilience and vulnerability. Here,
major advances and gaps are identiﬁed in our current
knowledge of arousal and stress regulation that highlight
possible causal treatment strategy's directed towards pre-
venting the precipitation of psychiatric disorders or promot-
ing mechanisms of resilience present in the disordered
brain.
2.1. Deﬁnition
Arousal is deﬁned as a state of being conscious, awake and
alert, which is required for information processing underlying
all cognitive functions and emotional expressions. According
to an operational deﬁnition (Pfaff et al., 2007), an animal or
human with higher generalised arousal shows greater sensory
alertness and enhanced mobility, and is more reactive
emotionally. Arousal is crucial for motivating various beha-
viours including sexual activity, exercise, the anticipation of
a reward, and coping with stressful experiences.
Stress is deﬁned “as a composite multidimensional con-
struct in which three components interact: (i) the input,
when a stimulus, the stressor, is perceived and appraised,
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output, or stress response. The three components interact
via complex self-regulating feedback loops that are
initiated by a stressor which is any change in the environ-
ment that disturbs homoeostasis (Levine, 2005).” The goal
of the stress response is to restore homoeostasis through
behavioural and physiological adaptations. The original
deﬁnition by Hans Selye was extended from a psychological
perspective, because the individual usually spends consid-
erably more time to anticipate a stressor – either real or
imagined – than actually suffering from it.
Arousal not necessarily causes a stress response, but the
reaction to a stressor is always preceded and accompanied
by arousal, particularly in cases of an adverse experience.
The most arousing and stressful condition is a situation of
uncertainty where there is no or ambiguous information,
poor predictability of upcoming events and lack of controll-
ability during the stressful experience, but with a fearful
anticipation of worry and other cognitive-emotional repre-
sentations of inability to cope. The impact of such a
stressor, that is usually chronic and repetitive, is modulated
by a variety of factors such as personality traits, self-
esteem, sense of safety, social rank and social support or
combinations of these psychosocial contexts (Lazarus, 2006;
Fink, 2007; Taylor, 2010a; Koolhaas et al., 2011).
An organism incapable to launch a stress response will
succumb and die. Alternatively, if an organism is unable to
turn off its stress response vulnerability to disease is
enhanced. A dysregulated stress response is not restricted
to a single organ, but rather affects the coordination
between cells, tissues, organs, systems and behaviour.
Vulnerability is enhanced when this coordination becomes
compromised. Hence for understanding the relationship
between stress and disease it is essential to understand
the functioning of circuitry in the brain that help appraise,
cope and adapt to environmental stressors.2.2. State-of-the-art
2.2.1. Organisation of arousal and stress systems
Arousal and stress are distinct, but partial overlapping
constructs. What distinguishes arousal and stress is their
biological substrate. If novel sensory input is perceived, it
produces an alarm reaction that is initially processed by the
nucleus gigantocellularis of the brain stem causing general-
ised arousal by enhanced activity of ascending excitatory
pathways (Csete and Doyle, 2004). Arousal governs activa-
tion of the reticular activating system in the brain stem, the
sympathetic nervous system and the neuroendocrine sys-
tem. Arousal, caused by glutamate-enhanced excitability, is
modulated by the classical neurotransmitter systems and by
neuropeptides that induce behavioural and physiological
activations characterised by increased attention, alertness
and vigilance.
Novel adverse signals are evaluated by processing the
information in the limbic-cortical circuitry. If the outcome
of the appraisal process in these circuits is interpreted as a
threat to integrity, the individual attempts to cope with the
stressor by initiating physiological responses for defence
and mobilisation of energy and to execute behaviours that
facilitate adaptation. Bodily inﬂuences are integrated in thecentral stress circuitry as well and signals of the immune,
cardiovascular–kidney, gastro-intestinal and metabolic sys-
tem affect brain function either directly or via the nervus
vagus. The stressful information from body and brain
converges with inputs from various neural networks such
as the arousing brain stem neurons from the locus coer-
uleus, and feeds into relay stations: e.g the amygdala
complex and the hypothalamic paraventricular nucleus
(PVN) (Herman et al., 2003).
2.2.1.1. Limbic – cortical circuits. The amygdala generates
emotionally loaded information, which is labelled in time,
place and context while processed in e.g. the hippocampal
formation (Eichenbaum et al., 2007). In mutual feedback
and feedforward loops the amygdala and hippocampus com-
municate with frontal brain regions, notably the mesolimbic –
cortical DA pathways of reward and adversity, and the
prefrontal cortex of which subregions are involved in speciﬁc
higher cognitive functions, as well as mood, affect, emo-
tional and stress regulation (Grace, 2010).
All this information converges in the PVN, which organises
the autonomous and neuroendocrine responses to stressors,
i.e. the sympathetic nervous system and the hypothalamic-
pituitary-adrenal (HPA) axis, that ultimately feedback to
the limbic and arousal circuitry. These limbic-cortical
circuits show during and in the aftermath of the stressful
experience a profound functional and structural adaptation
that is regulated by neural and hormonal factors by
modulating molecular signalling pathways. A new science
is emerging dedicated to calibrate and monitor these
adaptive changes as indices of vulnerability, resilience and
energy expenditure. This is the science of allostasis and
allostatic load (McEwen and Gianaros, 2011).
2.2.2. Temporal organisation
Arousal and stress regulatory systems operate in distinct
temporal domains:
2.2.2.1. Basal rhythm and sleep/wake states. The para-
sympathetic nervous system is dominant in the resting state,
at a time that the arousal and stress systems operate in a basal
state of activity. The latter systems display circadian rhythms
controlled by the circadian clock in the suprachiasmatic
nucleus entrained by the diurnal light-dark cycle. Moreover,
the HPA-axis shows hourly ultradian pulses, particularly of
cortisol. These cortisol pulses vary in amplitude over the
circadian cycle (Lightman and Conway-Campbell, 2010) with
highest amplitude at the circadian peak. The organisation and
pattern as reﬂected in the pulse amplitude and frequency of
the ultradian rhythm can vary in spikes depending on the
psychological and physical condition of the individual.
It is thought that the pulsatile rhythm enables synchroni-
zation and coordination of daily activities and sleep-related
events. In the elderly, the organisation of the ultradian
rhythm disappears and becomes desorganized which explains
why old individuals may have compromised sleep- and daily
activity patterns. Also the ultradian and circadian rhythms
provide a basis for the threshold and sensitivity of the stress
system: the magnitude and nature of the behavioural and
physiological stress response varies depending on the phase
of the hourly cortisol pulse (Sarabdjitsingh et al. 2010).
2.2.2.2. Response to stressors. The stress-induced HPA-
axis activity has two modes of operation that can be
separated in distinct temporal domains: a fast activation
G. Schumann et al.10representing primary defence reactions, which are then
slowly dampened to prevent these initial reactions from
overshooting and becoming damaging themselves (Sapolsky,
2000; Joëls and Baram, 2009). Overall the fast and slow
domains of the stress reaction aim to defend the integrity of
the organism and to restore homoeostasis. While doing so the
systems operate in concert to facilitate activation and to
promote adaptation and recovery, and to store the experi-
ence in the memory in preparation of a future experience.
The energy required to maintain the balance between
activation and adaptation contributes to the allostatic load.
How the HPA-axis is activated by stressors is well-
documented. The stressor activates through multiple inner-
vating pathways the PVN neuropeptide secreting cells that
produce a cocktail of CRH, vasopressin, angiotensin II (and
from elsewhere other neuropeptides such as e.g. PACAP and
oxytocin) and are released in the portal vessel system to
activate the synthesis and release of proopiomelanocortin
(POMC) peptides including the endorphins and melanocortins.
ACTH stimulates the adrenal cortex to secrete the glucocor-
ticoids cortisol and corticosterone, which feedback precisely
on the limbic-cortical circuits that have generated the initial
stress reaction. This action exerted by a single glucocorticoid
hormone has an enormous diversity, which depends in its
pattern on temporal, contextual and site-speciﬁc factors.2.2.3. Chronic stress and vulnerability to psychiatric
disorders
If coping fails repeatedly the reaction to the stressful
situation is reinforced and adaptation may occur to the
chronic stress condition. Selye indicated this General Adap-
tation Syndrome as the ‘resistance’ phase that slowly
develops over a period of weeks after the initial stress
(alarm) reaction. Upon chroniﬁcation this may ultimately
culminate in the exhaustion phase characterised by break-
down of adaptation. McEwen calls the adaptation to stress
‘allostasis’ meaning that in the context of the organism-
wide stress response the brain has the capacity to maintain
homoeostasis through changes in circuits, synaptic structure
and function, and behaviour. The cost of allostasis is termed
‘allostatic load’, a term that describes the individual's state
or ‘stress’ during Selye's resistance phase.
In such a chronic stress condition profound changes take
place in the stress system. Chronic stress produces in basal
state desynchronization of circadian cycles and sleep–wake
states, and evokes REM sleep abnormalities that accompany
depression and other psychiatric disorders. An elevated
sympathetic tone and activation at inappropriate times is
one aspect. A ﬂattened circadian and ultradian pattern of
HPA-axis activity caused by an enhanced magnitude of
cortisol pulses at the trough is then a characteristic feature
of the dysregulated neuroendocrine stress activity of a
severely depressed individual (Holsboer and Ising, 2010).
2.2.3.1. Structural plasticity. The functional and struc-
tural plasticity of limbic circuitry allows adaptation to either
excessive or inadequate cortisol responses. In response to
chronic stressors the apical dendrites of neurons in the
hippocampus CA3 region and areas of the prefrontal cortex
atrophy (McEwen and Gianaros, 2011). At the same time the
dendritic organisation of neurons of the basolateral amygdala
and orbitofrontal cortex become hypertrophic.Chronic stress also affects the fate and embedding of
newborn neurons into circuitry of the hippocampal dentate
gyrus and discrete regions of the olfactory brain, a process
that was shown to produce functional changes (Fitzsimons
et al., 2013). The organisation and function of the newly build
circuitry is therefore affected by stress, while other studies
have demonstrated enhanced neurogenesis after antidepres-
sants. Yet, even though small circuit changes can have
profound consequences, the function of neurogenesis in
psychiatric disorders, if any, still needs to be elucidated.
2.2.3.2. Resistance and hypersensitivity. During chronic
stress the balance changes between the central CRH drive
and the cortisol feedback potential, i.e. the actual setpoint
of the HPA-axis regulation. The drive depends on the
sensitivity of the stress system which is also under control
of cortisol. When either resistance or hypersensitivity to
cortisol develops one way or the other, the rest of the body
and brain is exposed to aberrant levels of the circulating
hormone. Thus, in case of elevated cortisol levels due to
feedback resistance, immune function is suppressed, the
bones are osteoporotic and a cardio-metabolic syndrome
may develop that is hazardous for physical health. This
further aggravates changes taking place in the brain. Like-
wise if too little cortisol is circulating the glucocorticoid
may be inadequate to restrain sympathetic nervous activity
and other stressful reactions, including the action of pro-
inﬂammatory and pro-immune cytokines.
The dynamics of the acute stress response in individuals
with a history of chronic stress experience can be used as
endocrine marker to monitor the allostatic load in the
resistance phase. Under chronic stress the acute activation
of the HPA-axis can be more profound, while it takes a
longer time to shut off the HPA-axis responses to stressors.
This enhanced responsiveness of the HPA axis suggests that
under conditions chronic stress, the stress system has
become sensitised to acute stimuli. Interestingly, this
sensitization to acute stimuli also occurs in subjects that
have become habituated to adversity, but is of course more
pronounced under persistent conditions of adversity to
which the individual did not habituate (Herman, 2013).
The sensitization is caused by altered signalling pathways
underlying the adaptation in structure and function of the
limbic-cortical circuitry, as well as the enhanced synthesis
capacity in the HPA-axis. The excessive and prolonged
cortisol secretions are linked to emotional and cognitive
disturbance rather than to depression per se.
The escape from suppression by the synthetic glucocorti-
coid dexamethasone has assisted in diagnosis of cortisol
resistance at the pituitary level (Ising et al., 2005). In
contrast, other adaptations after a single traumatic experi-
ence may occur that lead to low circulating cortisol levels
because of hypersensitive feedback at the pituitary-
hypothalamic level in the face of a very high sympathetic
tone as is the case for post-traumatic stress disorder (PTSD)
(Yehuda and Seckl, 2011). Hence, the feedback status can be
monitored in the dexamethasone (dex) suppression test or
dex-CRH test, the latter in cases that the central hyperdrive
to the pituitary is mimicked by exogenous CRH.
2.2.3.3. Molecular basis. Important advances have been
made in understanding the signalling pathways underlying
the activating and suppressing modes of stress system
operation. Thus, using advanced gene technology speciﬁc
11Medicine for mental disorderscircuits have been identiﬁed for the action of CRH, vaso-
pressin and the steroids in the different contextual and
temporal phases of the stress response (Refojo et al., 2011).
An ultrashort feedback loop has been identiﬁed in ﬁne-
tuning cortisol function via FKBP5 (Menke et al., 2013).
Cocktails of co-regulators are capable to modulate local
cortisol actions from agonism to antagonism and novel
glucocorticoid analogues are becoming available with
less side effects (Zalachoras et al., 2013). Intracellular
metabolism appeared an important regulator of bioavail-
ability of cortisol (Wyrwoll et al., 2011). Genetic poly-
morphisms have been identiﬁed that have profound effects
on emotional expressions and cognitive performance.
An important issue in understanding adaptation to stress is
the possibility that sensitization to stressors actually occurs by
switching to novel circuits and signalling pathways. There is
indeed supporting evidence for this thesis for humans and
animals where stress causes a switch between multiple
memory systems, i.e. from a hippocampal spatial strategy
towards a caudate-based habit learning strategy (Dias-Ferreira
et al., 2009; Oitzl et al., 2012). Also gene expression proﬁling
technology revealed that a history of chronic stress caused
sensitization to acute stressors or an acute cortisol challenge
by switching to alternative molecular pathways underlying the
processing of stressful information (Polman et al., 2012).
Stress affects the expression of genes involved in DNA
methylation and modiﬁcation of chromatine structure and
other aspects of epigenetic processes, particularly when
experienced during early life or adolescence. These data
suggest enduring changes in the transcriptome induced by
stress mediators during these sensitive windows of brain
development. The changes occur in the mediators and their
receptors of the HPA-axis, and also in the limbic-cortical
circuitry (Murgatroyd and Spengler, 2012).
2.2.4. Conclusion
Genes and neuronal circuits do not act by themselves but
need to be regulated by signals from environmental changes,
and the mediators of the arousal and stress systems are
extremely important for this purpose. Our position is that
dysregulation of the arousal and stress mediators may com-
promise mechanisms of resilience that can, thus, enhance the
vulnerability to psychiatric disorders. The identiﬁcation of
biomarkers in the arousal and stress systems themselves is
therefore an important objective in understanding the patho-
genesis of stress-related psychiatric disorders. It is recognised
that the repair and normalisation of a dysregulated arousal
and stress system is the key towards causal treatment of
psychiatric disorders.
2.3. Major advances
2.3.1. Technical innovation
Understanding the signiﬁcance of arousal and stress systems
requires approaches that link changes in molecular signal-
ling cascades with the plasticity of neural circuitry and
behaviour. New approaches using genetics or imaging or the
combined methodology of imaging genetics have led to
considerable advances in knowledge (Akil et al., 2011). It is
now feasible to examine the whole genome for responsive
genes, to identify haplotypes, copy-number variants andepigenetic proﬁles using the next generation sequencing
technology and computational biology. Functional connec-
tivity is examined in human and animal brains with powerful
fMRI and diffusion tensor MRI. In experimental animals
noninvasive optical methods are developed to turn on or
off speciﬁc genes in discrete neural circuits (Deisseroth,
2012). The generation of transgenic animals or lentiviral
delivery of gene constructs is a common practice. Electro-
physiological approaches as well as multiphoton imaging and
calcium imaging technology add to the study of circuit
dynamics and synaptic plasticity.
Using these methods it becomes feasible to examine the
circuits involved in the processing of arousing sensory informa-
tion stemming from olfactory, auditive, gustatory, vestibular
and visual inputs. Also the major ascending neurotransmitter
pathways relaying and integrating sensory information into the
arousal mode of the brain can be monitored. These include
the (nor)adrenergic, dopaminergic, serotonergic, cholinergic
and histaminergic neurons that innervate speciﬁc brain regions
involved in a variety of functions involved in emotional and
cognitive processes, motivational aspects, executive opera-
tions and motor outputs.
Then, neuropeptides coordinate, synchronise and activate
circuits underlying e.g. adaptive and social behavioural pro-
grams. These neuropeptides include the opioids and other
melanocortins, vasopressin, oxytocin, orexins and a variety of
other neuropeptide families capable to modulate and direct
circuits underlying stress adaptation and energy allocation. On
top of this, the ‘classic’ hormonal systems governed by
metabolic, sex and stress hormones exert an action capable
to programme the brain during critical periods of development
and to operate as master-switches during behavioural adapta-
tion, reproductive behaviour and energy metabolism.
2.3.2. Conceptual advances
2.3.2.1. Stress mediator signalling and susceptibility path-
ways. Several hypotheses of psychiatric disorders have
been developed based on dysregulation of the stress system.
These hypotheses include the anxiogenic actions of excess
CRH (Holsboer and Ising, 2010). Also the glucocorticoid
cascade hypothesis, which states that the rising glucocorti-
coid concentrations due to chronic stress downregulate
their GR leading to a vicious cycle that ultimately precipi-
tates stress-related brain disorders (Sapolsky, 2000). Cortisol
action is however also mediated by a second brain receptor
system, the mineralocorticoid receptors (MR)
MR has an exclusive localisation in brain areas involved in
processing of emotional and contextual information, while
GR is found in every cell. Due to its properties MR is crucial
in appraisal of novel information rapidly triggering emotions
and thus the onset and progression of the stress reaction.
GR controls the off-button of the stress reaction by slowly
promoting cognitive functions and memory storage for
coping with future events. Imbalance of MR and GR
enhances vulnerability to stress-related mental disorders.
Such an imbalance may occur with genetic variants of the
receptors or of their co-regulators and chaperones such as
operating in the ultrashort FKBP5 – GR protein feedback
loop (Menke et al., 2013), or due to epigenetic modiﬁcation
induced by environmental inputs.
The reactive alleles associated with emotions appear
crucial for vulnerability and resilience to psychopathology.
G. Schumann et al.12A striking example is presented by the carriers of the short
allele of the 5HT transporter which are more reactive to
negative life experiences, but also to positive experiences,
if compared to carriers of the long-allele (Canli and Lesch,
2007). Also BDNF variants have been associated with
affective states and are implicated in the plasticity hypoth-
esis of depression (Pezawas et al., 2008). Recently, MR
variants were found associated with appraisal processes,
dispositional optimism and protection against depression
(Klok et al., 2011). The other side of the coin are the non-
reactive alleles which can be equally damaging, as for
example in callous unemotional traits and psychopathy.
Unbiased genomic approaches have identiﬁed potential
susceptibility pathways linked to glutamatergic transmission
and glucocorticoid actions leading to rapidly acting keta-
mine and the antiglucocorticoid mifepristone. Gene expres-
sion proﬁling has provided a large number of glucocorticoid
responsive genes and pathways in the hippocampus, which
can be further pinpointed to neuro-anatomically deﬁned
areas by using laser capture dissection. This type of analysis
revealed CREB binding protein, BDNF and the mammalian
target of rapamycin (mTOR) signalling pathways, which play
a central role in translational control and have long-lasting
effects on the plasticity of speciﬁc brain circuits (Polman
et al., 2012). These pathways may serve as biomarkers for
stress-induced vulnerability.
2.3.2.2. Programming by (early) life experience and
epigenetics. A major advance is that an epigenetic mechan-
ism is evolving that underlies programming of emotional and
stress reactivity during critical times of brain development
with lasting consequences over the life span. Epigenetic
changes may involve DNA methylation, while complemen-
tary histone acetylation, methylation and phosphorylation
in response to stress presents also a novel candidate
mechanism (Meaney, 2010). The studies have demonstrated
that stressful experiences during early life can remodel
brain circuitry underlying emotional regulation. The out-
come of early life adversity can be modulated by maternal
inﬂuences and frequently investigated models are animals
that have experienced as pup reduced or fragmented
maternal care. Such a period of early neglect enhances
the pup's responsivity to adverse emotional experiences and
was found to advance prematurely the development of
emotional and fear circuitry involving cortisol and the locus
coeruleus NE input (Sullivan and Holman, 2010).
An increasing number of studies highlight the impact of
various contexts during prenatal and postnatal early life,
puberty and adulthood on the mechanism of resilience and
vulnerability to psychiatric disorders. Depending on these
contexts as well as experience-related factors and genetic
input, aggravation may occur either along the cumulative
stress hypothesis of psychopathology or the predictive
adaptation hypothesis. The latter hypothesis predicts that
rather a mismatch between early life experiences and later
life context enhances the vulnerability to a psychiatric
disorder (Nederhof and Schmidt, 2012).2.3.3. Conclusion
The adult brain shows plasticity in response to stressful
experiences and we are beginning to understand its poten-
tial in vulnerability and resilience to psychiatric disorders.The mechanism underlying plasticity involves among exci-
tatory transmission contingent on monoamine modulation
also arousal and stress system mediators which power the
impact of environmental inﬂuences (Joëls et al., 2012).
During critical periods in development these mediators can
cause lasting changes in circuitry involved in regulation of
emotional expressions and the stress response. Adaptations
to the programmed emotional circuitry in later life may lead
to vulnerability and resilience depending on environmental
context and genetic background.2.4. Questions to be solved
2.4.1. How can early experience precipitate a resilient
or vulnerable phenotype
To address this question it is crucial to understand that how
early experiences can programme perinatally and during
puberty emotional and stress regulations for life. This
requires insight in epigenetic and epistatic mechanisms that
can change brain plasticity towards a vulnerable phenotype,
which may become expressed under speciﬁc circumstances
in later life. Unresolved is why some individuals progres-
sively fail to cope with stress and accumulate risks for a
mental disorder, while others show adequate coping and
gain strength even from seemingly abusive early life adver-
sity as if such conditions prepare for life ahead.
For this purpose humanised models are needed that test the
mismatch or the cumulative stress hypothesis. Such models
depend on modulations of gene–environment interaction in a
living organism which will beneﬁt enormously from technolo-
gical advances in imaging, gene modiﬁcation and cell biological
technology. In fact, we are witnessing a constant renewal of
technology to address in these models the same questions: who
is at risk, and how do we prevent and cure disorders; how can
the quality of life, particularly of the elderly, be improved.2.4.2. How can a stress response change from
protective to harmful?
This question calls for research in appropriate models from
gene to behaviour linking the molecular mechanism with a
deﬁned neuro-anatomical substrate. This mechanism may
underly appraisal of a perceived arousing stimulus followed by
processing of potential stressful information. Whatever the
outcome of processing, the stress response promotes consolida-
tion (or extinction) of the experience in the memory in
preparation for the future. The question calls for research to
examine the impact of chroniﬁcation of the stressful experience
on structure and function of the brain. Does it trigger a switch
in circuitry or signalling cascades as recent research suggests? Is
sensitization of the stress system a hallmark of resilience or
vulnerability? The answer to these questions may give leads
towards therapeutic interventions to promote a mechanism of
resilience present in the disordered brain by modulating the
brain's plasticity and connectivity in speciﬁc circuits.
A testable hypothesis in this reasoning is that chronic stress
(high cortisol) may precipitate a depressive phenotype by
inducing downregulation of 5HT function accompanied by
enhanced anxiety or aggression, brieﬂy cortisol-induced ser-
otonin-dependent anxiety/aggression-driven depression (van
Praag et al., 2004; van der Kooij and Sandi, 2012).
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2.5.1. Gap nr 1 refers to the enormous complexity and
diversity in signalling mechanisms that are being
identiﬁed, explored each in its own right, but all for one:
the individual
The translation of the new knowledge, from signalling
cascades to the functioning of the human brain in health
and disease, is still poorly understood. The key towards
this understanding is in the arousal and stress systems
which operate in a higher order mechanism to coordinate
and synchronise the functions of all cells and organs over
daily activities and sleep-related events, and in coping
with challenging situations. However, with a bewildering
diversity in signalling mechanisms between individuals
cells.2.5.2. Gap nr 2 refers to individual differences in stress
responsiveness and consequences for brain function and
mental health over the lifespan, in males and females
That the arousal and stress system operate at the root of
individual differences in coping abilities and life trajectories
is common knowledge, but how this system is capable to
mobilise psychosocial resources for better and for worse is
not known. These resources include recruitment of social
support, the attained social position (socio-economic status)
and traits like dispositional optimism, mastery (control) and
self-esteem in which the stress system mediates the effect
of external demands and mobilises previously stored inter-
nal experiences and coping abilities. It is essential that
gender differences and parental behaviour is included in
this type of studies as well.2.5.3. Gap nr 3 is the lack of reliable biomarkers to
predict which individuals are vulnerable or resilient to
psychiatric disorders
Better insight into these mechanisms of vulnerability and
resilience may help to identify genes and their epigenetic
modiﬁcation inﬂuencing critical pathways that may on the
one hand serve as biomarkers to identify individuals at risk, i.
e. to monitor and calibrate allostatic load. These very same
pathways may deliver clues how on the other hand individuals
are capable to mobilise psychosocial resources to confer
health protective beneﬁts. It is complex because the outcome
of gene environment interactions is context-speciﬁc, and
governed by predictions from either the cumulative stress or
the mismatch hypothesis.2.6. Needs
The study on causality of stress and arousal systems in the
pathogenesis of psychiatric disorders requires multidisci-
plinary research groups capable to do studies from gene to
behaviour in a translational approach. To maintain the high
level of some already existing European research environ-
ments and to develop new frontline groups; standardisation
of approaches and sharing of new technologies are essential.
Training in concepts, theories and experimental approaches
is also needed on site and in dedicated schools.2.6.1. Integrated arousal-stress system clinical /
functional phenotype – genotype proﬁles
Ever since Selye coined the stress concept, it is well
documented that chronic unpredictable and uncontrollable
stress is a risk factor for psychiatric disorders over the
lifespan but how the stress-induced onset and progression
of these mental disorders takes place is still not well
understood. Since the arousal and stress system mediators
are central to the disorder an approach is needed that
integrates three levels simultaneously in the patients
(de Kloet et al., 2005; Taylor, 2010b; Binder and Holsboer,
2012). The personality and the clinically relevant phenotype of
emotional reactivity and reward mechanisms in the
context of psychosocial resources and neuro-imaging
data of limbic – prefrontal connectivity and plasticity. The functional phenotype as represented by neuro-
endocrine response patterns shaped by (early) life
experiences and characterised by biomarkers (Foley and
Kirschbaum, 2010) and predicted by the science of allos-
tasis and allostatic load (McEwen and Gianaros, 2011). The genotype of the patients based on (epi)genetic
predispositions in the arousal and stress mediators
themselves as represented by HPA-axis hormones and
their receptors as well as the 5HT/NE/DA systems,
CRH, vasopressin, oxytocin and other neuropeptides. A
validated test for common stress genes would count
about 200 hits and can be expanded with functional
variants/haplotypes and epigenetic markers (Pfaff
et al., 2007).2.6.2. Stress and arousal mediators: action mechanism
A wealth of data is available about how stress system
mediators are synthesised, released and act. One of the
sobering ﬁndings is that the hormones have an enormous
diversity in action on the molecular and cellular level, and
yet they can act as integrators over time and coordinators
of cell, tissue and organ functions as well as behavioural,
autonomic and immune responses under threatening cir-
cumstances. To understand these integrative mechanisms
basic science is needed with the goal: to identify – given the individuality and plasticity of
personal genomes and environments – individually
unique mechanisms converging on common susceptibil-
ity pathways leading to impairments. This would serve
as an inroad to novel biomarkers of stress and arousal
systems critical for assessment of vulnerability and
resilience. To develop humanised models by modiﬁcation of genes in
particular environmental contexts using genetic varia-
bility to identify novel susceptibility pathways and
mechanisms of brain (synaptic) plasticity. This could
integrate the interaction between genetic variability
and susceptibility to develop epigenetic changes in
response to stress; a systems approach is needed to analyse
the overall outcome of gene environment interaction. To translate the outcome of these gene–environment
interactions – as imposed by the action of arousal and
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psychiatric disorder.2.6.3. Psychiatric disorders and physical health
Brain–body interactions on the one hand reﬂect the impact
of the environment on mental and physical health, and on
the other hand the devastating inﬂuence of physical dis-
eases on higher brain functions underlying emotion and
cognition. These brain–body interactions depend on arousal
and stress system mediators (Hellhammer et al., 2012). It is
according to these authors therefore important: To understand how environmental circumstances such as
socio-economic status either linked to physical or psy-
chological deprivation or to the psychosocial impact of
social hierarchy, can promote arousal and stress system
dysregulations leading to disease. Likewise the beneﬁcial
effects of e.g. lifestyle, exercise and cognitive brain
therapy need to be translated into bona ﬁde brain
mechanisms. To understand how stress mediators not only communicate
neural information that aggravates cardio-metabolic-
inﬂammatory disease conditions, but also how these dis-
ease conditions can affect mental health. An increasing
body of evidence suggests in these interactions a crucial
role of hormonal and autonomic synergis
3. Cognitive systems
A new approach to psychiatry in terms of neurocognitive
systems is proposed which encompasses processes of percep-
tion, attention, working memory, long term memory, execu-
tive functioning, decision-making, metacognition and social
cognition. Critical techniques and conceptual approaches
include sophisticated human neurophysiology, ‘brain train-
ing’, functional connectivity and neural network analysis,
neurocomputation, mechanisms of neural plasticity and
animal models. New psychological theory will reinvigorate
neuroimaging approaches in all modalities and neuropsycho-
pharmacological investigations. These approaches will enable
the identiﬁcation of biomarkers (or neurocognitive endophe-
notypes) to provide alternative, dimensional descriptions of
neuropsychiatric endophenotypes in order to reach a more
accurate mapping of genetics with neuropsychiatric pheno-
types, the use of ‘purer’ (more homogeneous) populations for
clinical trials, and the identiﬁcation of vulnerabilities, and
hence the possibility of early detection and early interven-
tions or treatments for disorders such as schizophrenia and
depression. Following a review of the current status of
research in the ﬁeld (‘State of the Art’) and recent advances
(‘Major Advances’), we identify speciﬁc issues in each of the
main domains surveyed, as well as gaps and needs for future
advances in this research area. The main problems posed in
the European context are the need for collaborative research
(i) to help compensate for the withdrawal of many pharma-
ceutical companies from the ﬁeld, and also (ii) to provide
multi-disciplinary investigations of suitably large populations
of patients with the major neuropsychiatric disorders, to
allow deﬁnitive phenotypic descriptions and the effective
application of genomics.3.1. Deﬁnition
Psychiatric disorders implicate deﬁcits in many cognitive
systems, as well as their interface with affective, includ-
ing motivational, and social processes. Cognitive systems
may include processes of perception, attention, memory,
learning, thinking and executive function (including deci-
sion-making, problem solving and planning).3.2. State of the art
In the past two decades advances in cognitive neuroscience
in tandem with these interfaces have promised to revolutio-
nise our understanding, and potentially treatment, of dis-
orders such as schizophrenia, depression, neurodevelopmental
disorders such as ADHD, and addiction. Biological research into
mental disorders is plagued by vague nosological deﬁnitions
and boundaries which have often confounded psychiatric
genetics and led to the search for ‘intermediate’ neurocog-
nitive endophenotypes which may be core to particular
symptom clusters (see e.g. Robbins et al., 2012). These
endophenotypes may reﬂect basic building blocks of cogni-
tive function which are impaired in psychiatric disorders
because of malfunctioning controlling neurocircuitry. Such
‘building blocks’ derive from a decomponential analysis of
complex cognitive processes in the healthy brain, and may
include a variety of theoretical approaches, including rein-
forcement learning, decision theory, and cognitive constructs
(many of which are listed in the new NIMH initiative R.Doc),
such as working memory, and metacognition (including the
‘monitoring’ of cognition and thinking about the thinking of
others, ‘mentalising’, or ‘theory of mind’). These can be
analysed with a variety of methods, including neurocomputa-
tion, multimodal brain imaging (including PET, fMRI, and
electrophysiology) as well as neuropsychopharmacology and
animal models.
A fundamental distinction for psychiatry is that between
explicit and implicit cognitive processing, mainly reﬂecting
a dissociation between conscious processing available for
subjective commentary and covert, unconscious cognitive
mechanisms. This may also be paralleled by the contrast
between ‘top-down’ and ‘bottom-up’ processing. Many
psychiatric disorders are characterised by dysfunction at
both levels or by the interactions between the two. Deﬁcits
in cognition are increasingly being recognised as signiﬁcant
determinants of prognosis and rehabilitation, schizophrenia
being a key example. However, it is important to realise
that cognition comprises many components, including
perception, attention, working memory, declarative and
procedural memory, language, learning, decision-making
and planning, social behaviour and neuroeconomics con-
trolled by distinct, though overlapping neural systems or
networks, which are also co-ordinated and optimised by
sometimes poorly-characterised ‘executive’ functions, such
as cognitive control, inhibition and effort. The precise
relationship of executive functioning to metacognition (e.g.
theory of mind) processes is not well understood. These
cognitive components can be dissected by various labora-
tory cognitive tasks which are often customised for use in
neuroimaging studies and for use in psychiatric patients.
The expectation is that the application of these tasks in a
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methods will provide new, reﬁned measures of dysfunction
which will (i) improve the deﬁnitions of psychiatric pheno-
types (ii) better explain psychiatric symptoms (iii) enable
more homogeneous samples for treatment trials and (iv)
better predict vulnerability, risk and functional outcome,
including quality of life. We now describe some speciﬁc
examples and applications which illustrate the potential of
this exciting new approach.
3.3. Major advances
3.3.1. Perceptual dysfunction and electrophysiological
biomarkers
Subtle perceptual deﬁcits are present in many psychiatric
disorders, notably including schizophrenia and autism, that
may impinge on highly relevant capacities such as the
perception (and eventually the production) of emotional
pitch in spoken language. These dysfunctions are paralleled
by speciﬁc abnormal patterns of electrical brain activity,
namely attenuated or absent mismatch negative (MMN)
potentials to auditory, and even visual, stimuli. The MMN
is an auditory evoked potential measured by EEG, which is
generated by a bilateral superotemporal-frontal network
involved in auditory change detection. A common ﬁnding is
that schizophrenic patients have reduced MMNs elicited by
surprising stimuli that violate predictions established by
previous input history, e.g., with regard to expected dura-
tion or amplitude (Umbricht and Krljes, 2005). Abnormal
MMNs have been observed for mood disorders, ADHD, post-
stress traumatic disorders, chronic alcoholism, and a range
of neurological disorders, such as Alzheimer's disease,
Parkinson's disease, and stroke. Moreover, the abnormal
MMN found in this broad range of disorders points to a
common dysfunction in NMDA-mediated neurotransmission
(Näätänen et al., 2011). A major advantage of the MMN is
that it can be obtained even the absence of patient
collaboration, being elicited automatically in the absence
of direct attention. As well as MMN, studies on brain
connectivity (see below) can be implemented via neuro-
physiological techniques.
3.3.2. Attention and neural networks of cognition
Attentional deﬁcits are often among the most obvious
behavioural symptoms of psychiatric patients, but atten-
tional processes are diverse and one product of cognitive
neuroscience has been the recognition of a variety of
neuronal mechanisms and neural networks mediating dif-
ferent aspects, including selective, divided and sustained
attention. A recent major discovery of cognitive neu-
roscience has been that of the so-called ‘default system’
(comprising several midline structures such as the medial
prefrontal, and portions of the anterior and posterior
cingulate cortex and the pre-cuneus) which is deactivated
during most cognitive tasks requiring external orientation to
the world and generally activated during a wakeful resting
state in fMRI tasks or during periods of passive reﬂection
(Fair et al., 2008).
The study of ‘neural networks’ has expanded across many
scientiﬁc disciplines from social sciences to neuroscience due
to the discovery that complex interconnected and dynamicsystems can be described and analysed using a set of
mathematical techniques termed ‘graph theory’ (Sporns
et al., 2004). Brain graphs provide a relatively simple way
of representing the human brain as a comprehensive map of
neural connections, (the ‘connectome’). Using graph theory
the CNS can be represented as a set of nodes (denoting
anatomical regions or functional neuronal aggregates) and
interconnecting edges (denoting structural or functional
connections). Network analysis is being used to identify
neural changes in human neurological or psychiatric disorders
which may provide novel endophenotypes (or ‘biomarkers’)
for the purposes described above (Fornito and Bullmore,
2012). Additionally, during the periods of early brain devel-
opment and maturation, when it is clear many neuropsychia-
tric disorders originate, this method could be used to deﬁne
important dynamic changes of anatomical, functional and
effective connectivity [Functional connectivity is deﬁned as
the “temporal correlations between spatially remote neuro-
physiological events” (Friston et al., 2003), whereas effec-
tive connectivity is deﬁned as “the inﬂuence that one neural
system exerts over another either directly or indirectly”
(Friston et al., 2003)]. These network properties are being
studied with a mixture of electrophysiological (EEG, MEG and
transcranial magnetic stimulation) and functional imaging
methods, thus setting the foundations for novel approaches
to understand the brain ‘at work’ in health and disease.
Applications so far have ranged from Alzheimer's disease and
stroke to obsessive-compulsive disorder and schizophrenia,
re-conceptualising some of these disorders as complex
examples of ‘disconnection syndromes’.3.3.3. Working memory and cognitive training
The deﬁnition of working memory differs widely between
research areas. Important knowledge about neural mechan-
isms has come from electrophysiological and neuropharma-
cological studies of nonhuman primates, specifying delay
speciﬁc activity in prefrontal and parietal areas. Neural
network models have successfully made biologically realistic
models of reverberatory, re-entrant circuitry that maintains
the activity of cue-speciﬁc neurons. The neurophysiological
data are largely consistent with neuroimaging studies of
sustained activity in humans. There is an overlap between
‘top-down attention’ and ‘working memory’ regarding both
behavioural and neuroimaging ﬁndings and the relationships
between certain aspects of attention and working memory
need to be resolved. One promising facet of working
memory are the translational ﬁndings from animal and
human volunteer research that it is possible to enhance
working memory function acutely using pharmacological
treatments such as D1 dopamine receptor agonists.
Training can lead to sustained improvement of working
memory capacity, which also translates to improvements of
other executive functions relying on working memory and
top-down attention (Jaeggi et al., 2008), as well as
increased attentiveness in everyday life. This has implica-
tions for use as a remediating intervention for individual
where low working memory capacity is a limiting factor for
academic performance or everyday life. Working memory
training is the beginning of a new research ﬁeld exploring
the possibilities of enhancing other executive functions such
as self-control with help of computerised training methods,
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treatment (Klingberg, 2010).3.3.4. Long term memory and plasticity
Profound deﬁcits in declarative memory are not only pre-
sent in early Alzheimer's disease but also in schizophrenia,
probably as a result of overlapping pathology within the
medial temporal lobe, including the hippocampus. More-
over, stress can profoundly impact neuronal plasticity and
neurogenesis within the hippocampus relevant to a range of
affective disorders (Lupien et al., 2009). Considerable
neuroscientiﬁc advances have characterised molecular
mechanisms of plasticity relevant to memory consolidation
and extinction that may be related to such disorders as
pathological anxiety, post-traumatic stress disorder and
addiction. In particular, the phenomenon of memory recon-
solidation provides a basis for eliminating maladaptive
plasticity of memory circuits (Milton and Everitt, 2010).
These advances have also motivated the development of a
range of ‘cognitive enhancing’ drugs, often based on
potentiating glutamate neurotransmission through the
NMDA receptor.3.3.5. Decision-making, learning and
neurocomputation
Reinforcement-related decision-making cognition broadly
encompasses: how individuals learn the value of stimuli
(e.g. associations with reward or punishment); how those
stimulus values can inﬂuence choices and actions (both
explicitly and implicitly); and how conﬂicts between
different possible choices are resolved. In the human
decision-making literature, paradigms have often been
developed such that behaviours can be compared directly
with those seen in experimental animal models of psy-
chiatric disorders. The study of reinforcement-related
decision-making has important implications for under-
standing cognitive performance in other domains, since
tasks often feature elements that are intrinsically rein-
forcing (for example, performance feedback). Decision-
making deﬁcits in various forms have been found in
virtually all psychiatric disorders, including depression
and bipolar illness, addiction, attention deﬁcit/hyperac-
tivity disorder, obsessive-compulsive disorder and anti-
social behaviour.
Advances within the past decade include: the use of
formal computational approaches to analyse decision-mak-
ing; and the study of human behavioural phenomena
identiﬁed in the ﬁeld of economics (‘neuroeconomics’;
Glimcher et al., 2008). The neuroeconomics literature has
focused on understanding why humans depart from
rational, normative accounts of decision-making (such as
expected utility theory) when performing value-based
choice tasks. Examples include: loss aversion (the ten-
dency for losses to appear proportionately worse than
gains); risk aversion (the tendency to prefer certain out-
comes to risky outcomes); framing (the inﬂuence of the
way that a decision is presented on choice); and temporal
discounting (the preference for smaller, sooner outcomes
than larger more temporally distant ones). More generally,
there has been considerable expansion in the use of fMRI to
understand the brain bases of decision-making in (mainlyhealthy) volunteers, largely replicating an earlier animal
literature, and also a great focus on investigating the role
of chemical neurotransmitters in decision-making through
both experimental psychopharmacology and naturally-
occurring (e.g. genetic) variation. These investigations
have conﬁrmed important roles for the following brain
regions (among others) in decision-making: striatum; orbi-
tofrontal cortex; anterior cingulate; amygdala; pallidum;
thalamus; the midbrain dopaminergic and serotoninergic
nuclei.
Computational modelling approaches are attractive as
they appeal more directly to mechanistic hypotheses and
can sometimes be directly linked to putative neurophysio-
logical processes. For example, reinforcement learning
theory has highlighted the importance of prediction errors
as teaching signals for learning and has related these to
phasic ﬁring of midbrain dopamine neurons (Schultz, 1997).
This has triggered a wide range of investigations into
psychiatric diseases, trying to understand maladaptive
behaviour as a consequence of aberrant prediction error
processing and learning (e.g. Murray et al., 2007).
These approaches differ from previous attempts to
correlate brain signal with clinical data in some important
ways: ﬁrst, explaining behavioural observations in terms of
mathematical models of the underlying computations (e.g.
by assessing learning rates and prediction error signals in
different disorders, see Park et al., 2010), can dissect out a
number of inﬂuences on behaviour that may be conﬂated
together using traditional measures (e.g. the number of
errors made on a probabilistic learning task might be
inﬂuenced by both the learning rate and the deterministic
nature of responding). Second, the systematic use of
statistical model selection, which enables one to disam-
biguate between competing models (hypotheses) and
select the model that generalises best (i.e., has the best
trade-off between accuracy and complexity) allows infer-
ence on ‘hidden’ quantities that are otherwise very
difﬁcult to measure (e.g. neuronal processes that underlie
measured EEG, fMRI or behaviour). This particularly ben-
eﬁts from combining computational models with physiolo-
gical models (e.g., how prediction errors drive short-term
synaptic plasticity of task-relevant circuitry denOuden
et al., 2010). These model-based estimates of hidden
physiological quantities can dramatically increase both
sensitivity and interpretability of diagnostic classiﬁcation
based on imaging (Brodersen et al., 2011). Third, recently
developed Bayesian model selection procedures account
for population heterogeneity, speciﬁcally the possibility
that patients may solve problems differently and hence
display alterations in brain signals that simply reﬂect
alternative cognitive strategies and not biological differ-
ences (Stephan et al., 2009). The use of computational
modelling will thus enable us to look at cognitive mechan-
isms and their behavioural and biological correlates in a
manner that cuts across traditional disease entities (Heinz,
2002; Robbins et al., 2012).
Recent computational approaches to decision-making
often take a Bayesian perspective (Behrens et al., 2007;
Mathys, 2011; Frank and Badre, 2011) which is beginning to
be applied routinely in pharmacological (e.g., Passamonti
et al., 2012) and clinical studies (Averbeck et al., 2011).
Moreover, the Bayesian model comparison is becoming a
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making, including reinforcement learning models (Shiner
et al., 2012). Notably, the Bayesian model selection can also
be applied to assess which model (e.g. single SNP vs.
haplotype analysis) is most appropriate for explaining
genotype x phenotype interactions (Puls et al., 2009).3.3.6. Metacognition, executive function and social
cognition
Metacognition includes thinking about the thinking of others,
where it is usually called mentalising or theory of mind (ToM).
There is ample evidence that both these aspects of meta-
cognition are impaired in psychiatric disorders, in particular
schizophrenia and autism. A particular aspect of metacogni-
tion of great relevance to psychosis is insight. Lack of insight
is one of the deﬁning features of psychosis.
The monitoring and control of cognition is also referred to
as ‘executive function’ (EF). Several studies suggest that EF
and ToM can be impaired independently of one another, but
this is not always found, one problem being that EF is not a
single entity. Recent developments in the study of ToM have
revealed the existence of an implicit form (Senju et al.,
2009). In autism there is evidence that implicit ToM is
impaired, while the explicit form is intact, or at least can
be acquired. Implicit ToM is closely linked to the other major
theme in social cognition. This theme involves such phenom-
ena as emotional contagion, mirroring of action and learning
through observation/imitation of others (Rizzolatti et al.,
1996). These phenomena underlie implicit ToM. Many tasks
have been developed for the study these aspects of social
cognition and are being applied to the study of autism.
Considerable advances have been made in computational
modelling of mechanisms of top-down control. These are
often described in terms of a Bayesian algorithm that
optimally combines prior expectations (the top-down com-
ponent) with new sensory evidence in order to determine
perception and behaviour (Fletcher and Frith, 2008). This
approach has been most successful in relation to under-
standing the experience of action and delusions of control
(Frith, 2012). There is now much evidence for failure in the
adaptation or updating of predictions (i.e. prior expecta-
tions), based on prediction errors, in schizophrenia.
Theory in social cognition has been enriched by the
cognitive neuroscience of social decision-making that has
derived from the study of economic games (such as ‘the
ultimatum game’ (e.g. Sanfey, 2003) or “the prisoner's
dilemma”).3.3.7. Conclusion
We have summarised some of the main themes for psychiatry
arising from a cognitive neuroscience approach. This new
approach evidently embraces advances in both methodology
and theory: virtually all of the conceptual themes outlined
above can be associated with such developments. As noted in
the Introduction, one product of the approach will be the
deﬁnition of more accurate psychiatric phenotypes. Another
will be in the development of new treatments, whether
cognitive, electrophysiological or pharmacological. An exam-
ple of the general process would be initially establishing
relationships between neural processing, behavioural perfor-
mance and decision-making models. The ﬁtting of a modelwould then allow identiﬁcation of dysfunctional processes
and potentially a suitable target for therapeutics. The
application of the cognitive systems perspective will neces-
sarily involve interfaces with other approaches, e.g. with
respect to affective systems, comorbidity and psychiatric
genetics. We have not attempted in this brief review to
relate dysfunctions of speciﬁc neural systems to underlying
molecular pathology and neurogenetics, but these will also
be important goals.
3.4. Questions and problems to be solved
3.4.1. Perceptual dysfunction and electrophysiological
biomarkers
Future research should focus on establishing animal, human
electrophysiological and neurocomputational models of
short-term plasticity subserving regularity encoding, and
mechanisms of deviance detection, as to provide a solid
basis for the use of the MMN, and related human electro-
physiological responses as markers of cognitive dysfunction
in psychiatric disorders.
3.4.2. Attention and neural networks of cognition
A detailed understanding of network properties of cognitive
systems will enable the rational development of emergent
procedures of deep brain stimulation and transcranial
magnetic stimulation (Rossini and Rossi, 2007), as thera-
peutic interventions for disorders such as obsessive-
compulsive disorder and depression, and potentially other
indications.
3.4.3. Working memory and cognitive training
There are many questions yet to be answered regarding
cognitive training, including: what are the optimal tasks to
use for training; what is the optimal training regime in
terms of amount, length and spacing of training; how can
training be tailored individually; what are the neural and
biochemical correlates of training-enhanced capacity; and
can the training effect be enhanced by a combination with
other interventions, such as other types of cognitive train-
ing, medication or cardiovascular training?
3.4.4. Long term memory and plasticity
A notable challenge for the next period is whether the
preclinical development of compounds with relatively new
modes of action, including various ways of boosting gluta-
matergic transmission, can be translated to the clinic,
possibly via experimental medicine and back-translation
studies.
3.4.5. Decision-making, learning and
neurocomputation
Future research will need to focus on parsing the contribu-
tion of different aspects of learning to decision-making
relevant to neuropsychiatric disorders; for example, the
distinction between Pavlovian, instrumental (goal-directed)
and habit-based learning systems, which have been shown
to have different neural substrates, and their relationships
to valuation, including the subjective hedonic response to
receiving a reward. Again, such effects can be assessed
using the same computationalized approach in animal
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entities (Robbins et al., 2012; Huys et al., 2011). These will
beneﬁt from further development of ‘hybrid’ models that
allow for inference on disturbances of synaptic plasticity in
individual patients by combining physiological models of
neuronal dynamics with computational models of trial-wise
prediction errors (c.f. denOuden et al., 2010). Finally, the
existence and workings of opponent motivational systems,
as has been posited for example in addiction, also remains
to be characterised.
Knowledge generated by better understanding decision-
making may be critical in improving the diagnosis, treat-
ment and nosology of mental health problems. The most
straightforward translational targets would include: depres-
sion (where anhedonia and difﬁculty in decision-making are
diagnostic features); schizophrenia (where motivational
impairments [apathy] and anhedonia are key negative
symptoms that pose a barrier to rehabilitation); and sub-
stance dependence (where addictive drugs effectively hijack
the brain's reinforcement-based decision-making circuitry).
Better understanding of the different reinforcement-based
decision-making deﬁcits in these conditions, and their neural
bases, will additionally be of importance in the development
of novel and more valid, animal models of psychiatric
disorder.3.4.6. Metacognition, executive function and social
cognition
We need to specify which components of EF are relevant to
ToM. Part of this new research will involve the development
of new and better tasks for measuring ToM abilities. More
studies of metacognition in psychosis are also required; for
example, new tasks are needed for contrasting implicit
and explicit metacognition, especially in relation to ToM.
Following the achievements of applications of studies of
social cognition studies to autism, similar studies are
needed for psychosis. Moreover, we will need to consider
whether a computational account of delusions is feasible
based on work on expectancies and prediction errors.
Deviations from the ‘rational’ concept of human decision-
making approach assumed by economic theory are highly
relevant to psychiatry and may provide a rich new source of
measures and concepts.3.5. Gaps
Given the considerable advances in other aspects of neu-
roscience, including molecular genetics and new ways of
imaging the CNS at all levels, there needs to be a greater
interdisciplinary integration of these advances with the new
concepts of neuropsychiatric disorder emerging from the
theoretical opportunities afforded by cognitive neu-
roscience. At present the best routes to achieve this may
stem from (i) the development of more realistic animal
models to bridge the gap in genetics, improving the avail-
ability of new sensitive PET ligands to measure molecular
changes in the disordered brain; and (ii) deﬁning more
detailed connectomics through cellular and systems imaging
in various modalities and application of electrophysiological
methods, in order to facilitate the more sophisticatedapplication of therapeutic methods such as deep and non-
invasive brain stimulation.
3.6. Needs
There is an urgent need to provide new research groups or
networks to help compensate for the void left by big Pharma
into research into therapeutics in this area. Such groups
would combine expertise in relevant areas from molecular
and genetic to the methodology of cognitive neuroscience
for improved deﬁnitions of disease endophenotypes and
assessment of new therapeutics. These groups would also
combine clinical neuroscientists to enable experimental
medicine studies, with basic neuroscientists, including those
working with experimental models and cognitive neu-
roscience. Collaborative networks will increasingly be
needed for investigating the large populations needed to
investigate psychiatric disorders, in order to resolve the
difﬁculties posed by their heterogeneity.
4. Positive and negative valence
Positive and negative valence are evolutionarily essential
states underlying two opposite behavioural tendencies:
reward and punishment. Given the fundamental importance
of reward and punishment-related behaviour it is unsurprising
that maladaptive forms of these traits are a pervasive
component of psychopathology, most often associated with
anxiety and mood disorders as well as substance and
behavioural addictions. Here, we provide an overview of
the state of the art of biomedical research on positive and
negative valence, describing ﬁndings at the following levels:
(1) genetic, molecular and cellular level, including mole-
cular mechanisms of environmental inﬂuences and systems
approaches. (2) Circuit and physiological levels where we
review brain structures and neural circuits associated with
different behavioural manifestations of positive and nega-
tive valence, including reward, reward learning, habit, fear,
anxiety and sustained threat. (3) Clinical and behavioural
level, including studies in humans on addiction and affective
disorders, anxiety and schizophrenia. We describe major
advances in the respective research areas and identify key
challenges for future research, necessary to characterise
and develop speciﬁc treatments that target pathological
processes involving positive and negative valence rather
than heterogeneous categories of mental illness.
4.1. Deﬁnition
Positive and negative valence are evolutionarily essential
states underlying two opposite behavioural tendencies:
approach and withdrawal also referred to as reward and
punishment. These two opposite ancestral behaviours guide
an organism to generate the necessary responses to search
for life-supporting events and to avoid harms. Thus they
warrant survival and evolution and are highly conserved
states common to vertebrates, reptile birds, amphibians
and probably to other simpler species like invertebrates
(Alcaro and Panksepp, 2011; Huber et al., 2011; O’Connell
and Hofmann, 2011). Given the fundamental importance
these behaviours it is unsurprising that maladaptive forms of
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most often associated with anxiety and mood disorders as
well as substance and behavioural addictions.
In the Research Domain Criteria (RDoC) approach motiva-
tion, initial responsiveness to reward, sustained responsive-
ness to reward, reward learning and habit have been
proposed as constructs related to positive valence. For
negative valence, the proposed constructs are: active
threat (“fear”), potential threat (“anxiety”), sustained
threat, loss and frustrative nonreward. The use of these
constructs may allow a more translational approach that
will permit researchers to understand positive and negative
valence on a genetic, molecular, cellular, systems and
behavioural level and from that may allow inference of
important concepts for the neurobiology of psychiatric
pathologies.4.2. State of the art
4.2.1. Genes, molecules and cells
Human genetic studies thus far have not usually investigated
positive and negative valence as such but have mainly
analysed the genetic contributions to maladaptive reward
and punishment-related behaviour in clinical samples. These
include genome-wide association studies (GWAS) on tobacco
smoking (Thorgeirsson et al., 2008; The Tobacco and Genetics
Consortium, 2010; Liu et al., 2010), alcohol drinking beha-
viour (Schumann et al., 2011) and other addiction pheno-
types. Similarly, GWAS studies analysing both common
variants, as well as rare variants and copy number variations
have been carried out in mood disorders, including bipolar
disorders (Ye et al., 2012), and major depression (Ripke
et al., 2013), often ﬁnding common polygenic variation
contributing to more than one disorder (Smoller et al., 2013).
These, non-hypothesis driven, human genomic investiga-
tions as well as studies in animals have identiﬁed diverse
classes of genes and molecules associated with positive and
negative valence. It thus became increasingly evident that
in addition to neurotransmitter systems, other types of
molecules are equally important including cell-cell adhesion
molecules, cytoskeleton and synaptic molecules, transporters
not only of neurotransmitters but also amino acids, neuroster-
oids, second messenger systems, transcription factors and
others. Consequently, this highlighted the importance of brain
cells other than neurons for the neurobiological regulation of
behaviour. These include astrocytes and microglia as well as
modulatory inﬂuences of peripheral cells such as immune cells
(Eroglu and Barres, 2010; Graeber, 2010; Miller et al., 2009).
Understanding the neurobiological functions of the genes and
genetic variations thus identiﬁed and assessing their relevance
for positive and negative valence is a critical challenge to
better understand the neurobiological basis of reward and
punishment in psychopathology and normal behaviour.
Positive and negative valences are constructs which are
captured rather well in behavioural animal models. In fact,
animal studies have been crucial in elucidating neurobiolo-
gical circuitry of reward and punishment-related behaviours
and have thus helped identify candidate genes for further
studies. Conversely, animal studies are invaluable tools to
functionally characterise those GWAS hits, which do not
easily ﬁt into existing neurobehavioural concepts. Anexample is the demonstration in mice of dramatically
increased nicotine intake associated with polymorphisms
of the CHRNA5 gene, encoding the α5 subunit of the
nicotinic acetylcholine receptor (Fowler et al., 2011). Good
animal models exist for constructs related to threat and
reward, whereas constructs such as loss are beginning to
emerge (Huston et al., 2013). Important advances in our
understanding of the genetic underpinning of positive and
negative valence have been made possible by an increasing
number of molecular tools, allowing site- and timing speciﬁc
manipulations of speciﬁc genes as well as the study of
human genetic polymorphisms in laboratory animals (Barr
et al., 2003; Carola and Gross, 2012; Chen et al., 2006; Kaun
et al., 2011; Müller and Holsboer, 2006; Soliman et al.,
2010; Stewart et al., 2012).
Increasingly studies have shown signiﬁcant interactions
and correlations of environmental factors with genetic
factors inﬂuencing phenotypes related to both positive
and negative valence. Environmental factors relevant for
both positive and negative valence, such as stressful life
events, parental attachment have been shown to have
effects not only on speciﬁc genes, but on a large number
of loci, to possibly allow orchestrated changes across
several systems. For example, McGowan et al. (2011) have
reported that the epigenetic response to maternal care is
coordinated in clusters across broad genomic areas and not
restricted to single candidate genes. In addition, data
emerge that miRNA can be stress sensitive and orchestrate
gene expression changes in a number of important target
(Haramati et al., 2011). An important emerging concept,
related to the molecular mechanisms of positive and
negative valence is that inherited genetic variation in sites
determining miRNA transcription, environment induced
epigenetic changes or the effects of transcription factors
could have broad effects on a number of downstream
systems and targeting such master regulators may be
promising preventive or therapeutic approaches.4.2.2. Circuits and physiology
As stated above, positive and negative valence are highly
conserved states. Hence, it is not surprising that the
neuroanatomical correlates of these responses consists of
ancient neuronal structures, which include the basal gang-
lia, the amygdaloid complex, the hypothalamus and other
conserved areas of the brain. Of note, however, research
has also shown that in evolved species such as human and
nonhuman primates evolutionarily recent neuronal struc-
tures including the neocortex also play a role in shaping
these responses thus suggesting that unique features may
distinguish these species from others (Noonan et al., 2012).
A common feature of positive and negative valence states
is that they both guide a live organism to emission of goal
oriented responses, in the ﬁrst case to approach the reward
in the second to avoid the threat (Everitt and Robbins,
2005). Accordingly, these two opposite emotional states are
regulated largely by the same neurotransmitter systems,
and their ﬁne tuning is responsible for approach and reward
or withdrawal and aversion. This has been described for
dopamine (DA) serotonin (5-HT), noradrenalin (NE), opioids,
corticotropin releasing factor (CRF), orexin and others.
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unravelling neuroanatomical and functional correlates of
reward and appetitive responses originates from the semi-
nal work of Olds and Milner (1954) showing that rats learn
electrical self-stimulation when an electrode is placed in
the lateral hypothalamus-medial forebrain bundle. Subse-
quent studies demonstrated that activation of the meso-
limbic DAergic A10 pathway originating from the ventral
tegmental area (VTA) and projecting to the nucleus accum-
bens (Nac) is a key neurocircuitry in reward processing
and positive salience attribution (Volkow et al., 2009). The
opioid system has been also implicated in the regulation of
reward mechanisms and positive valence attribution. The
major role appears to be played by the μ-opioid receptor
system which acts through at least two neuroanatomically
distinct mechanisms (Johnson and North, 1992). Brain
imaging studies using PET ligands to monitor DAergic as
well as μ-opioidergic activity in response to drugs of abuse
have conﬁrmed these preclinical ﬁndings (Heinz et al.,
2005; Volkow et al., 1997).
4.2.2.2. Positive valence: reward learning. A positive
valence of a stimulus may trigger ‘wanting’ and ‘liking’
in an organism (Robinson and Berridge, 1993). Thereby the
‘wanting’ predominantly determines approximatory and
consummatory behaviour while ‘liking’ describes subjective
pleasure and estimation of a stimulus. ‘Wanting’ determines
behavioural plasticity and is a key to psychopathologies like
obsessive compulsive disorders and addiction (Robinson
and Berridge, 2001, 2003). It is assumed that ‘wanting’ is
particularly driven by DA activation in the mesolimbic
system (Wise, 2004; Berridge, 2007). DA neurons in the
VTA increase ﬁring rate after presentation of an uncondi-
tioned stimulus (UCS) with positive valence (Hollerman and
Schultz, 1998). In natural habitats, certain stimuli may
predict the availability of the UCS with positive valence.
This natural contingency can be learned and a formerly
neutral stimulus may become a conditioned stimulus (CS),
which can by itself trigger conditioned responses. This
learning process is supported by a transfer of the DA
activation from the UCS to the CS (Hollerman and Schultz,
1998; Roitman et al., 2004).
It should be noted that mesolimbic DA activity is not only
important for behavioural adaptations towards stimuli
with a positive valence. DA appears equally important for
adaptations to stimuli with negative valence. Those may
require active avoidance responses, which may also get
more efﬁcient once guided by predictive cues (Ikemoto and
Panksepp, 1999). Extracellular DA levels in the Nac increase
not only after positive stimuli but also after negative ones
(Young et al., 1993). Likewise, there are DA neurons in the
dorsal VTA which increase phasic ﬁring predominantly after
negative stimuli (Brischoux et al., 2009). Current evidence
suggests that there are at least two different populations of
VTA DA neurons projecting to the Nac or prefrontal cortex
(PFC), one type coding for positive and one for negative
events (Hollerman and Schultz, 1998; Brischoux et al., 2009;
Lammel et al., 2011, 2012).
4.2.2.3. Positive valence: habit. Stimuli with a positive
valence may trigger approach and consummatory behaviours.
During an early phase of instrumental conditioning, beha-
vioural plasticity is outcome controlled and relies on Nac DA
activation (Ikemoto and Panksepp, 1999). With increasingexperience a behavioural response may become a habit. The
behaviour is no longer dependent on its outcome, but only on
predictive cues (Everitt and Robbins, 2005). Habits are
mediated by the dorsolateral striatum (DS) and its dopami-
nergic innervation (Yin et al., 2004; Faure et al., 2005).
There is a spiralling loop projection which links the VTA-Nac
dopaminergic projection to the substantia nigra-DS projec-
tion (Haber et al., 2000). Via this loop behavioural control
can be shifted from outcome-controlled to stimulus-
controlled. During early learning of e.g. cocaine self-
administration behaviour, predominantly the ventral stria-
tum is recruited. With increasing learning trials also the DS
becomes involved (Porrino et al., 2004). Functional studies
have shown that activation of these loop projections are
crucial for the transfer of outcome- to stimulus-controlled
behaviour (Belin and Everitt, 2008).
4.2.2.4. Negative valence: responses to acute threat
(fear). Activation of the brain's defensive motivational
system promote behaviours that protect the organism from
perceived danger. Normal fear involves a pattern of adap-
tive responses to conditioned or unconditioned threat
stimuli (exteroceptive or interoceptive). Fear can involve
internal representations and cognitive processing, and can
be modulated by a variety of factors.
The neurocircuitry and physiology involved in response to
acute threat (fear) has been extensively studied in non-
primate animals, especially rodents, and in non-human
primates and in healthy humans. Experiments typically
involve classic condition and extinction learning or use
unconditioned threat stimuli using molecular and electro-
physiological studies as well neuroimaging methods. The
‘fear’ circuitry consists of the amygdala, the hippocampus,
the dorsomedial and ventromedial prefrontal cortex, the
anterior cingulate cortex, the orbitofrontal cortex, the
insular cortex, and a number of brain areas involved in
initiating physiological and behavioural responses (Shin and
Liberzon, 2010). These latter areas are the periaquaductal
grey, ventral striatum, brainstem nuclei (autonomic nervous
system) and hypothalamus (HPA-axis). A distinction can be
made between the ‘fast’ or quick and dirty route and the
slower, indirect one that allows regulation of the initial
response by higher cortical areas.
4.2.2.5. Negative valence: responses to potential harm
(anxiety). Activation of a brain system in cases in which
harm may potentially occur, but is distant, ambiguous, or
low/uncertain in probability, characterised by a pattern of
responses such as enhanced risk assessment (vigilance).
These responses to low imminence threats are qualitatively
different than the high imminence threat behaviours that
characterise fear.
The anxiety circuitry has been less studied and charac-
terised as compared to fear circuitry, especially in humans.
Typically used paradigms are darkness in humans or light in
rodents or slowly ﬂuctuating indicators of potential risk,
typically leading to an enhanced speciﬁc environmental
threat monitoring. Work in rodents and non-human primates
has shown this type of hypervigilant monitoring to be more
dependent on involvement of the bed nucleus of the stria
terminalis (BNST) and its reciprocal connections with the
central nucleus of the amygdala. Recent neuroimaging
studies have implicated the BNST, the insular cortex and
lateral prefrontal cortex in anxiety in healthy humans
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circuitry correspond with higher trait anxiety.
4.2.2.6. Negative valence: sustained threat circuitry. This
construct refers to an aversive emotional state caused by
prolonged (i.e., weeks to months) exposure to internal and/
or external condition(s), state(s), or stimuli that are adap-
tive to escape or avoid. The exposure may be actual or
anticipated; the changes in affect, cognition, physiology,
and behaviour caused by sustained threat persist in the
absence of the threat, and can be differentiated from those
changes evoked by acute threat.
The concept of sustained threat is applicable to subclini-
cal and clinical forms of anxiety, but also to other stress-
related states, probably including some depressive sympto-
matology. It is a more complex construct than the previous
two, because of its broad deﬁnition (internal/external,
weeks to months, actual or anticipated exposure etc.).
The sustained threat circuitry and physiology overlap with
those of fear and anxiety, but also include frontostriatal
circuitry and probably circuitry involved in for instance self-
processing in humans (Shin and Liberzon, 2010).
4.2.3. Behaviour and clinical
4.2.3.1. Positive valence. Alterations in reward processing
are a component of psychiatric disorders, including sub-
stance use disorders, eating disorders and behavioural
addictions as well as affective disorders and schizophrenia
(namely negative symptoms). Each reward-related illness is
characterised by its own collection of aetiological predis-
posing factors, psychopathological dysregulations and symp-
toms. Identiﬁcation of speciﬁc mechanisms and risk factors
underlying the different clinical presentations will enable
the development of individualised diagnostics and targeted
prevention and therapeutic strategies. However, clinical
presentations of maladaptive reward processing also share
important common features.
In the case of addictive behaviours, dopaminergic activation
of the reward circuitry through substances as well as natural
reinforcers appears to be crucial for development and early
stages of addictive behaviour (Bassareo and Di Chiara, 1997,
1999; Lutter and Nestler, 2009; Volkow et al., 2012). A better
understanding of similar and distinct mechanisms underlying
the development of addictive behaviours is one important
challenge of the ﬁeld.
The later stages of addictive behaviours involve allostatic
changes of the brain reward system that is shifted towards a
hypohedonic state (Eshel and Roiser, 2010; Le Moal and
Koob, 2007) and contribute to the compulsive character of
habit formation. This may involve a switch from positive
valences to negative valences as the motivational driver
maintaining addictions.
High comorbidity between addiction and depression or
psychosis has been also well documented (Nunes and
Rounsaville, 2006; Schuckit, 2006). Notably, both depressed
and psychotic patients appear to be more prone to abuse
addictive substances that, at least in part, are used to self-
medicate from the negative affect associated with the
primary disease. On the other hand, addiction is known to
trigger psychotic episodes and exacerbate depression in
some individuals, and is probably a cause of depression as
well (Munafò and Araya, 2010). The intimate nature of these
intricate disease interactions is unknown at present butalteration of brain reward processing seems to play a pivotal
role. A transdiagnostic approach to disorders has already
been used during the 1990s with positron emission tomo-
graphy investigations of the relationships between clinical
dimensions in affective or psychotic disorders and measures
of the dopamine system (e.g. Martinot et al., 2001). These
brain imaging studies were associated with controlled trials
aiming at improving the targeted clinical dimension.
4.2.3.2. Negative valence. Changes in fear/anxiety circui-
try, frontostriatal circuitry, and physiology (i.e. HPA axis and
autonomic nerve system) related to sustained threat have
been typically studied in animal models and in anxious and
depressive patients. The neurocircuitry of some clinical
anxiety states has been relatively well studied including
post-traumatic stress disorder (PTSD) and obsessive com-
pulsive disorder (OCD), but the ‘common’ anxiety disorders,
i.e. panic disorder, social anxiety disorder and generalised
anxiety disorder, in which the fear/anxiety circuitry is
believed to be the key circuitry involved, are understudied.
In PTSD and OCD the fear/anxiety circuitry is involved, but
other circuits are also clearly involved, especially in OCD
where frontostriatal circuitry is probably even more rele-
vant for the phenomenology (van den Heuvel et al., 2011).
Meta-analyses and reviews of functional neuroimaging
studies show the presence of a hyper-responsive amygdala
(and insula) across the different anxiety disorders, but
ﬁndings in the other elements of the circuits vary with
disorder and scan paradigm (Etkin and Wager, 2007). A
meta-analysis of more than 250 brain-imaging publications
on mental disorders in children and adolescents (Mana
et al., 2010) suggested that when various types of brain
imaging techniques are collapsed (i.e. brain coordinates of
functional or structural imaging deviations) the disorders
involving negative affects are characterised by reports of
abnormalities in amygdala, bilateral cingulate cortex,
bilateral middle (vmPFC) and inferior frontal gyri, caudate
nuclei and hypothalamus. In children and adolescents, the
group of affective disorders encompassed MDD, bipolar,
and anxiety disorders (except OCD). On the physiological
level, abnormalities in HPA axis regulation have been
demonstrated in anxiety disorders, most consistently
for PTSD.
4.3. Major advances1. Novel in-vivo neurobiological techniques involving geno-
mics, stem cell-biology, multimodal neuroimaging and
neuropsychology have facilitated characterizations of
cognitive functions at multiple biological levels, thus
crucially advancing our understanding of the human brain.
Increasing sample size in neuropsychiatric genome-wide
association studies have yielded multiple new genetic
associations and annotation of the function of these
variants will be a potential window into new biology.2. Progress in genomic and molecular techniques has
resulted in advances in our knowledge of processing of
reward and punishment. On a genetic level this includes
an appreciation of the limited contribution of single
genes even to behaviourally and neurophysiologically
circumscript phenotypes and the fact that genes and
gene products not immediately involved in
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punishment associated neurobiological mechanisms and
behaviours.3. On a systemic level we have learned much about the
interdependency of different neurobiological systems,
for example stress and reward system, circadian system
and reward system etc. There is a substantial body of
knowledge available for especially the fear and reward
circuitry, linking the circuitry to speciﬁc physiological
reactions, behaviour, genes, and neurotransmitters and
other psychotropic molecules.4. Neuroimaging analyses in humans, using both MRI and
PET have validated and extended neurobiological infor-
mation acquired from animal models. They have aided in
describing speciﬁc neurobiological circuits involving
reward and punishment and are indispensible to investi-
gate the relation of such circuits to observable beha-
viour, including psychopathology.5. Findings from transdiagnostic approaches in neuroimaging
studies suggest that to investigate the neurobiological
basis of psychiatric disorders, biological, biomarker and
human genetic studies need to move away from diagnosis
and symptom-based associations towards intermediate
phenotypes that might better reﬂect these domains
(Loth et al., 2011). For example, we hypothesise that
distinct neurobehavioural mechanisms such as reward
processing and impulsivity lead to adolescent substance
use. It was recently shown that speciﬁc brain networks
contributing to impulsivity are associated with adolescent
drug use behaviour, and a genetic variation in the
norepinephrine transporter gene (Whelan et al., 2012).
4.4. Questions and problems to be solved
However, to fulﬁl the promise of stratiﬁed psychiatric
diagnosis and treatment it is necessary to generate more
knowledge on reinforcement-related mechanisms, including
a better understanding of how valence contructs map to
clinical measures, a particular emphasis on normal and
abnormal development across the life span, as well as the
inﬂuence of environmental factors in humans. To achieve
this we need to further characterise at risk individuals at
the circuitry and molecular level and translate our ﬁndings
into clinical applications. This includes:1. Functional characterisation of neurobehavioural mechan-
isms across the life span. While the mechanism of action
of single molecules or some speciﬁc chain of molecular
events important for positive and negative valences have
been elucidated – (see Attwood et al., 2011; Spanagel
et al., 2005 as selected examples), our understanding of
how the many different types of molecules act in a
concerted way is insufﬁcient. One of the challenges in
the coming years will be to explore the systemic context
of such molecules on different cell types, investigate
their relation to our current molecular understanding of
the neural underpinnings of positive and negative
valence (Geschwind and Konopka, 2009) and assess their
function across the life span.2. In order to better understand the relation of individual
vulnerability/resilience in adverse conditions as well asthe consequences of a nurturing environment on reward
and punishment-related behaviour and mental health
in general we require better understanding of gene
environment interactions as well as gene environment
correlations (the genetic inﬂuences on environmental
exposure) and their mediation through epigenetic and
transcriptional mechanisms. Such studies will require
novel animal models as well as massive data sets if
current crude environmental measures are used due to
the modest effect sizes associated with single genes;
development of more relevant environmental measures
are sorely needed. On the other hand, as more and more
genes are identiﬁed to be associated, use of genetic risk
scores and genome-wide scores will bring much more
power to such studies, permitting analyses in sample of
reasonable size.3. Neurobiological pathways of progression from subclini-
cal/subthreshold state to clinical state which in the case
of addictions may reﬂect a change in valences driving
motivations for addictive behaviour, from positive
valence at the subclinical state to negative valence (dark
side) during chronic disease. For affective disorders this
is probably a more gradual progression in which adequate
processing of negative valences shift temporarily towards
sustained threat.4. Characterisation of underlying mechanisms for shared
and distinct symptoms of reward and punishment proces-
sing within and across disorders. Identiﬁcation of predictors
and prognostic markers for risk, disease progression and
therapy response.5. Identiﬁcation of treatment targets, both pharmacologic
and psychotherapeutic, and delivery of prophylactic, or
early intervention using therapies that target causal
mechanisms of disease.5. Systems for social processes
Social interactions represent a core feature of the human
species. The interpretation of social cues, facial expressions,
human actions and goal-directedness, allows the “social brain”
to produce constructs as complex as theory of mind and
empathy, resulting in amazingly multifaceted responses such
as altruism, sense of equity, love, and trust. Systems for Social
Processes (SSP) include neurobiological systems and psycholo-
gical functions that prepare individuals for social interaction,
while supporting the development of mental health and well-
being throughout the life of an individual. The present
contribution brieﬂy summarises social brain functions, span-
ning from socially relevant sensory input processing to infor-
mation processing yielding socially adaptive responses.
Questions and problems in different domain are identiﬁed,
as well as three overarching gaps present in current classiﬁca-
tion systems, affecting “validity”, “translation”, and “con-
tinuum-category”, and two SSP-speciﬁc “developmental” and
“environmental” gaps currently hampering appropriate recog-
nition and use of SSP deﬁcits in psychiatry. We ﬁnally identify
an urgent need to chart developmental and normative varia-
tion in each social domain, to design reliable tools able to
“weigh” environmental contributions to SSP, and multidisci-
plinary approaches aimed at integrating information from
multiple levels of analysis.
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Systems for Social Processes (SSP) refer to the intraindivi-
dual neurobiological and psychological systems and func-
tions that (1) develop both prenatally and postnatally
throughout the life of an individual, (2) prepare and set
up individuals for social interaction, and (3) are directly
relevant to support and promote development of mental
health and well-being and causal understanding, clinical
assessment, treatment and prevention of mental impair-
ment. A clear theoretical delineation of SSP from systems of
emotion, cognition and language is hardly possible and has
to be done pragmatically. The social brain is the cortical and
subcortical network of regions that underlies SSP. Its regions
include ventral and medial prefrontal cortex, superior
temporal gyrus, fusiform gyrus (FG), cingulate gyrus and
amygdala, which are specialized to process social informa-
tion such as the face, gaze, biological motion, human
action, goal-directedness, theory of mind and empathy.
Deﬁcits in SSP, either alone or in interaction with cognitive,
affective, and motor systems, are implicated in many
psychiatric disorders.
SSP build upon sensory systems including hearing, touch and
vision, extend into multifaceted socially-relevant processes like
empathy, recognition of emotional expression, imitation and
simulation involving mirror neuron systems, to yield constructs
as complex as theory of mind (social cognition), social
approach-avoidance, attachment, and self-representation.
5.2. State of the art
5.2.1. Hearing
Sounds produced by emotionally relevant ﬁgures accompany
humans throughout life ever since prenatal development.
Astonishingly, humans develop maternal voice recognition in
utero as early as at 33–34 weeks of gestation (Jardri et al.,
2012); mothers are able to discriminate the cries of their
own child from another's within 48 h of birth: this is a
feature shared with many gregarious mammalian species
(Pitcher et al., 2010) and thus it is genetically encoded,
neurobiologically hardwired, and evolutionarily conserved.
As all other senses, hearing does not analyse only the
physical properties of sounds but also their emotional
content, so much so that facial expression recognition is
signiﬁcantly delayed in preschoolers with congenital deaf-
ness or cochlear implants, as compared to normal hearing
children (Wang et al., 2011).
5.2.2. Touch
Touch plays an important role in our everyday social
interactions from birth through to adulthood and old age.
However, little scientiﬁc research has been conducted on
the topic of interpersonal touch. Tactile sensations elicited
under ecologically-valid conditions that involve interperso-
nal interaction can have powerful effects on people's
behaviours and emotions. Interpersonal touch appears to
be capable of modulating people's compliance with a variety
of different requests. Interpersonal touch can affect peo-
ple's attitudes toward particular services, facilitate bonding
between pairs in a couple or groups in both animals and
human, and it plays an even more important role in people'sromantic and sexual relationships, regardless of whether or
not the tactile contact itself can be remembered explicitly.
The emotional somatic system, similarly to pain sensation,
is temporally delayed as compared to discriminative touch
(McGlone et al., 2007).
The use of touch therapy, when properly trained, can be
very helpful when the child's development is in its very
critical stages early in life. By spending as little as thirty
minutes per day giving a child tactile stimulation increases
weight gain and cognitive reﬂexes, as well as the release of
hormones and neurotrophic factors, including IGF1, which
plays a trophic role in synaptogenesis (Field et al., 2008).
This has been shown in humans as well as animal models.
Children who have received regular tactile stimulation show
more cognitive stability as well as more social stability
(Bell, 2011).
5.2.3. Eye contact
Human infants already shortly after birth have innate
tendency to preferentially orient to social stimuli and look
at and process the face of other persons. Direct gaze signals
that the gazer is looking at the perceiver. In many species,
the perception of direct gaze elicits an aversive response,
probably because it is a salient signal for potential threat.
This response may be maintained in autistic individuals,
leading to reduced direct gaze at the eye-and-mouth facial
area, accompanied by reduced activation of the fusiform
gyrus and the amygdale (Corbett et al., 2009). In typically
developing children, by contrast, eye contact provides a
foundation of communication and social interaction. In the
ﬁrst months of life, eye contact develops into gaze following,
i.e. following the gaze movements of other person towards
salient stimuli. Next, in typical development, joint attention
behaviours emerge between 6 and 12 months and involve the
triadic coordination or sharing (‘jointness’) of attention
between the infant, another person, and an object or event
(Bakeman and Adamson, 1984). The term encompasses a
complex of behavioural forms including gaze and point
following, showing and pointing. Deﬁcits in joint attention
skills play an important role in the development of autism
spectrum disorders (Bakeman and Adamson, 1984).
5.2.4. Imitation
One may discern imitation of emotional and non-emotional
behaviours, and differentiate between automatic and
voluntary imitation. In particular the mirror neuron system
provides an important neural substrate for humans' ability
to imitate (Gallese et al., 1996). Meta-analyses using
activation likelihood estimation (ALE) seem to reveal that
the superior parietal lobule, inferior parietal lobule, and
the dorsal premotor cortex but not the inferior frontal
gyrus, are all commonly activated in fMRI studies of imita-
tion. This questions the crucial role of the frontal mirror
neuron area, the pars opercularis of the IFG, during imita-
tion and suggests that parietal and frontal regions which
extend beyond the classical mirror neuron network are
crucial for imitation (Molenberghs et al., 2009).
5.2.5. Empathy
Empathy is the capacity to recognise, understand and share
the emotional states of others (Decety and Jackson, 2004;
G. Schumann et al.24Decety and Moriguchi, 2007), and is considered to be the
cornerstone of genuine and reciprocal human relationships.
Lack of empathy has been invoked as an explanatory
mechanism in various forms of psychopathology, but fore-
most in autism spectrum disorders and conduct disorder.
Empathy is assumed to consist of three components: motor,
emotional, and cognitive empathy (Blair, 2005). Motor
empathy refers to automatically and unconsciously mirror-
ing the facial expressions of another person, known as facial
mimicry. Emotional empathy refers to the experience of
emotions consistent with and in response to those of others.
Cognitive empathy is the ability to rationally understand
and recognise the emotional state, and take the perspective
of other persons; so called Theory of Mind (ToM). The key
brain areas involved in empathy are the sensorimotor mirror
neuron system for motor empathy, the inferior frontal gyrus
for emotional empathy, and the ventromedial prefrontal
cortex for cognitive empathy (Baird et al., 2011). Naturally,
motor, emotional, and cognitive empathy are interdepen-
dent. The perception-action model posits that observation
of emotions activates neural circuits responsible for gen-
erating the same emotion and thus activating the motor
representation, i.e. motor empathy, and associated emo-
tional autonomic responses. This is suggested to result in
resonance with the emotional state of another person, i.e.
emotional empathy, and facilitating emotion recognition,
i.e. cognitive empathy. Automatically mimicking and syn-
chronizing emotions with other people facilitates emotion
recognition, social interaction, as well as empathic func-
tioning (Singer, 2006; Sonnby-Borgström, 2002; Stel and van
Knippenberg, 2008; Stel and Vonk, 2010).
Theory of mind (ToM) is a broader concept than empathy
and refers to the ability to understand mental states,
intentions, goals and beliefs, irrespective of the emotional
state and relies on structures of the temporal lobe and the
pre-frontal cortex (Singer, 2006). ToM has both cognitive
and emotional underpinnings, processed by two distinct, yet
highly interactive networks, the cognitive ToM network,
primarily engaging the dorsomedial prefrontal cortex, the
dorsal anterior cingulate cortex and the dorsal striatum;
and the affective ToM network involving the ventromedial
and orbitofrontal cortices, the ventral anterior cingulate
cortex, the amygdala and the ventral striatum (Abu-Akel
and Shamay-Tsoory, 2011). Although empathy and ToM are
often used as synonyms in the literature, these capacities
represent different abilities that rely on different neuronal
circuitry. Finally, the abilities to understand other people's
thoughts and to share their affects display different onto-
genetic trajectories reﬂecting the different developmental
paths of their underlying neural structures. In particular,
empathy develops much earlier than mentalizing abilities,
because the former relies on limbic structures which
develop early in ontogeny, whereas the latter rely on lateral
temporal lobe and pre-frontal structures which are among
the last to fully mature.5.2.6. Attachment
The neural basis of human attachment security is poorly
understood. Performance during a stress but not a neutral
prime condition was associated with response in bilateral
amygdalae in an fMRI paradigm. Furthermore, levels ofactivity within bilateral amygdalae were highly positively
correlated with attachment insecurity and autonomic
response during the stress prime condition. This suggests a
key role of the amygdala in mediating autonomic activity
associated with human attachment insecurity (Lemche
et al., 2006). On the other hand, the pleasure intrinsic to
secure human attachment and interpersonal relationship is
mediated by activation of reward circuits. In fact, synchro-
nous mothers, whose maternal behaviour is coordinated
with infant signals, display greater activations in the left
nucleus accumbens tightly coordinated with oxytocin
release, while intrusive mothers exhibit higher activations
in the right amygdala (Atzil et al., 2011). Adult attachment
representations are associated with neural, emotional and
behavioural responses to infant crying. Individuals with
insecure attachment representations showed heightened
amygdala activation when exposed to infant crying com-
pared to individuals with secure attachment representa-
tions (Riem et al., 2012). Amygdala hyperactivity might be
one of the mechanisms underlying the experience of
negative emotions during exposure to infant crying in
insecure individuals and might explain why insecure parents
respond inconsistently to infant signals and might even
become abusive. Intranasal administration of oxytocin, a
hormone that enhances parental sensitivity and parent-
infant bonding (Naber et al., 2012), decreases amygdala
responses and increases insula and IFG responses to infant
crying (Riem et al., 2011). These ﬁndings point to a role of
empathy-related brain regions in sensitive parenting and
adult attachment representations, and to the possibility of
psychopharmacological interventions.5.2.7. Recognition of emotional expression
Human social skills require the ability to adapt and regulate
instinctive reactions to emotional signals, in particular the
communicative signals of threat or appeasement conveyed
by emotional facial expressions (ÖHman, 1986; Blair, 2003).
In particular, the lateral OFC and the adjacent ventrolateral
prefrontal cortex are involved in the selection of actions
that override automatic and motivationally (reward) driven
response tendencies (Elliott et al., 2000; Passingham et al.,
2000; Rushworth et al., 2007). Numerous studies have
addressed the neural bases of perception of social emo-
tional signals, in particular facial expression (Adolphs,
2003), detailing the crucial role of the amygdala and other
limbic structures in the automatic processing of (negative)
facial expressions (Adolphs, 2002; McClure et al., 2004;
Strauss et al., 2005). The cerebral and cognitive mechan-
isms controlling the behaviour evoked by these perceptual
processes, i.e. approach-avoidance tendencies, appear to
be controlled by the lateral OFC (Roelofs et al., 2009).5.2.8. Self
The ‘self’ is a complex multidimensional construct deeply
embedded and in many ways deﬁned by our relations with
the social world. Normal individuals preferentially recruit
the middle cingulate cortex and ventromedial prefrontal
cortex in response to self compared with other-referential
processing. In particular, the self construct is hypothesised
to be embedded in the “default mode network” (DMN),
encompassing the middle frontal gyrus, frontal medial area,
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right pre-cuneus, bilaterally. Recent studies on several
pathological conditions suggest that the strength of DMN
functional connectivity could mediate the strength of self-
consciousness expression (Fingelkurts et al., 2012).5.2.9. Behavioural systems
Psychology and human communication research has identi-
ﬁed a number of behavioural systems that tend to be
organised rhythmically and to synchronise with other indi-
viduals during face to face interaction. These include
autonomous motivation for prosocial behaviour, mechanisms
of interpersonal attraction, gestures and mimicry. Impair-
ment of these systems is found across diagnostic categories
(Littlejohn and Foss, 2011).5.2.10. Language
Language, a central expression of human cognitive ability, is
the most powerful communication system that evolution has
produced. In addition to its strictly communicative uses,
language also has many social and cultural uses, such as
signifying group identity, social stratiﬁcation, as well as for
social grooming and entertainment. We all share the
capacity to acquire language within the ﬁrst few years of
life, without any formalized teaching programme. Language
is processed in many different locations in the human brain,
but especially in Broca's and Wernicke's areas. Language has
many different aspects, such as phonology, semantics and
syntax. Particularly relevant is here pragmatics, that is the
use of language in context. Linguistic pragmatics implies
difﬁculties in the ability to disambiguate meaning, the
ability to structure coherent discourse and to understand
irony and implied meaning. The ability to understand other
people's intentions, social rules of conduct and non-verbal
communication gestures are regarded as non-linguistic
pragmatics. Deﬁcits in pragmatic functioning may be evi-
dent at all developmental stages. There is hardly any
research on the relationship between pragmatic language
competence and the risk for psychiatric disorders and
behavioural problems (Adams, 2002).5.3. Questions and problems to be solved
5.3.1. Touch
Research has not yet uncovered why interpersonal touch
has such dramatic effects on people. Nor do we know all
that much about the cognitive, neural, and physiological
mechanisms underlying the effects of touch on social
interactions. Researchers have only just started to address
the neural aspects of interpersonal touch by showing that
different patterns of brain activation can differentiate
between the more perceptual and the more social aspects
of tactile sensation (Gallace and Spence, 2010; Gazzola
et al., 2012). Oxytocin (OT), a brain peptide, has been
implicated in maternal bonding, sexual behaviour and
social afﬁliation behaviours. OT is of potential use in
enhancing interpersonal and individual well-being, and
might have more applications in mental disorders espe-
cially those characterised by persistent fear, repetitive
behaviour, reduced trust and avoidance of socialinteractions (Ishak et al., 2011; Dunbar, 2010), or abnormal
attachment (perversion).
The signiﬁcance of mediated social touch needs to be
empirically established, and grounded within a multidisciplinary
theoretical framework that encompasses multisensory per-
ception, social psychology, and communication theory
(Haans and IJsselsteijn, 2005).
5.3.2. Hearing
The study of children with cochlear implants has thus far
mainly focused on the consequences of auditory deprivation
on hearing, speech perception, word learning and phonolo-
gical development. In this regard, novel areas of mounting
interest include social development and neurocognitive
processes. Different ages at onset of hearing impairment
also offer great opportunities to study the critical periods
for hearing contributions to social cognition, which see-
mingly do not overlap with those for language development.
This area of investigation is especially relevant to the design
of therapeutic interventions aimed at promoting interper-
sonal synchrony in children with hearing loss receiving
cochlear implants (Mellon et al., 2009). Also the role of
hearing in socially-relevant multisensory perception and
exploration still remains to be fully appreciated and
characterised.
5.3.3. Eye contact
Although it is commonly agreed that eye contact modulates
the development and activation of the social brain network,
the precise mechanisms and developmental processes
involved remain unclear. Two general accounts have often
been invoked to explain the mechanisms underlying the eye
contact effect. The affective arousal model argues that eye
contact directly activates brain arousal systems and/or
elicits a strong emotional response. This raised arousal or
emotional level then inﬂuences subsequent perceptual and
cognitive processing. Other researchers have argued that
eye contact directly activates theory-of-mind computations
or a pedagogy brain system because it signals the intent to
communicate with the perceiver. A more recent account,
the fast-track modulator model, presumes that the eye
contact effect is mediated by the subcortical face detection
pathway hypothesised to include the superior colliculus,
pulvinar and amygdala. This route is fast, operates on low
spatial frequency visual information and modulates cortical
face processing (Senju and Johnson, 2009).
5.3.4. Imitation
Imitation is a primary means through which children learn
new skills. Most children learn to imitate without being
taught but some children with disabilities fail to develop or
use imitation in the absence of direct instruction. Whether
this is due to an abnormal mirror neuron system, or whether
the mirror neuron system in these individuals is not fed the
necessary information due to direct gaze deﬁcits remains to
be conclusively established. More intervention studies are
needed to improve imitation skills in children with disabil-
ities, and to examine which strategies to improve imitation
are most effective. These strategies should include the
implementation of speciﬁc prompting cues; embedding
instructions across activities; teaching imitation of
G. Schumann et al.26multiple, salient models; and using reinforcing behaviours
and materials. Future research is needed on questions
regarding instructional sequence, effective instructional
practices, and measurement and promotion of generalised
imitation (Ledford and Wolery, 2010).
5.3.5. Empathy
There are two, typically distinctive views on how emotions
and action intentions are perceived by an observer. The ﬁrst
view stresses the importance of simulation, whereas the
second notion stresses the importance of mentalizing. At the
level of the brain, likewise a distinction is made between
simulation mechanisms linked with the fronto-parietal net-
work referred to as the Mirror Neuron System, and mental
inference processes, linked with the mentalizing network,
Theory of Mind. What is poorly understood is whether
simulation and mentalizing are completely independent
processes, reﬂect different styles of processing emotional
and social information at the levels of individual subjects,
have different developmental trajectories, and interact with
each other during development.
5.3.6. Language
There are many unanswered questions about “language in
action”, i.e. the relationship between linguistic and in
particular pragmatic competence and social and commu-
nicative ability: (1) How is multi-sensory information (e.g.
eye gaze, hand gestures such as in pointing) integrated with
linguistic information during social interactions? (2) What is
the role of action simulation or predicting other's goals (i.e.,
conceptual simulation) in language comprehension and
production? If one is able to predict the communicative
goals of a speaker, one might also be able to predict the
content and perhaps the form of their utterances. (3) What
is the contribution of cognitive control to language planning
and processing? Accumulating evidence suggests that cog-
nitive control over language processes is achieved by goals
and rule systems that interact with basic language func-
tions, including lexical memory. (4) How does pragmatic
language competence interacts with social processes in
modulating risks for the onset and course of psychiatric
disorders (Mahon and Caramazza, 2008; Hagoort, 2005)?
5.4. Gaps
At least three overarching gaps, shared with other areas in
Mental Health, and several SSP-speciﬁc gaps can be identi-
ﬁed at this time. The general gaps include:
5.4.1. The validity gap
The current classiﬁcation systems (ICD/DSM) are not very
suitable to handle failures in SSP.1. Although failures in SSP are among the most socially
impairing handicaps in human life, there is no single
diagnosis for SSP-failure. Most frequently SSP-failure is
only one of several interchangeable criteria underpinning
a diagnosis (e.g. social anxiety, autism, several person-
ality disorders).2. Several obvious clinical phenomena where SSP failure is a
core problem, are not covered by the current diagnosticsystem (e.g. shyness vs. unsocial personality traits;
callous/unemotional vs. reactive/impulsive aggressive
behaviour; lonely mass murderers).3. Because failure in SSP is a core problem across a large
number of both mental developmental, personality and
symptom disorders and only to a modest degree con-
tribute to differentiation between diagnostic categories,
failures in SSP often go undiagnosed. Psychiatric disor-
ders also encompassing SSP failure or SSP distortions
among several clinical features are typically diagnosed
neglecting SSP whereas symptoms pertaining to the
behavioural or cognitive domains are much more fre-
quently set as diagnostic criteria (schizophrenia, affec-
tive disorders, etc).
5.4.2. The translation gap
The current classiﬁcation systems (ICD/DSM) are largely
based on clinical opinions, often weakly related to current
knowledge in SSP neurobiology and neurochemistry. This
dissociation between basic science and clinical experience
is a major barrier for translation of ﬁndings from basic to
applied research, assessment and intervention.
5.4.3. The continuum-category gap
As long as we try to force continuous/dimensional phenom-
ena into discrete categories, patients with impaired SSP will
by necessity frequently end up with several co-morbid
diagnoses and the explanatory power/explanation of var-
iance in these categorically deﬁned “diseases” will continue
to be modest.
Until these three overarching gaps have been closed,
scientiﬁc achievements in the ﬁeld of mental disorders will
by deﬁnition continue to be modest.
Additional SSP-speciﬁc gaps include:
5.4.4. The developmental gap
Normative data describing the developmental trajectory of
different key components of SSP in typically developing
paediatric populations are largely not available. This lack of
European- and nation-based reference data hampers both
scientiﬁc research and a clinically-usable deﬁnition of SSP
failure, currently available only for major global SSP
deﬁcits.
5.4.5. The environmental gap
While genetic, neurochemical and neuroimaging approaches
usually provide reliable quantitative data, environmental
factors are often overlooked in biomedical research or lack
appropriate tools to approach their complexity and provide
some measure of their relative “weight”. This dramatically
reduces the reliability of gene x environment interaction
models and their explanatory potential, when considering
the amount and complexity of the variance involved in
human social processes.
5.5. Needs
5.5.1. Developmental studies
There is a critical need for developmental behavioural and
neuroscience studies in all these different components of
27Medicine for mental disordersSSP. These should chart developmental and normative
variations, obtain reference values for key components as
eye-contact, face scanning, and emotional responsivity,
and describe the neurobiological bases of behavioural
phenomena observed by developmental psychologists many
decades ago.
5.5.2. Environmental studies
Practical and reliable tools to measure SSP-related phe-
nomena known to bear a major impact on the later
development of mental disorders, on their onset or their
clinical course, as well as on stable personality structures
associated with social malfunctioning are urgently
needed. Examples include measures of intrafamilial inter-
actions and family structure, mother–child synchronicity
during neonatal life, and peer interactions in social net-
works or work environments (or, more in general, social
structure).
5.5.3. Integrative approaches
Experimental and statistical paradigms, able to integrate
information obtained through multiple different approaches
into unitary paradigms by employing artiﬁcial adaptive
systems for data mining in hypothesis-driven and
hypothesis-free experimental designs. Areas which could
especially beneﬁt from objective and measureable multi-
disciplinary approaches include the study of parent-child
interactions, as well as SSP-related multisensory perception
and exploration.
These needs essentially refer to the SSP-speciﬁc gaps
summarised above. Their satisfaction represents a pre-
requisite to then confront the three general gaps, having
developed solid and broad-based normative data, appro-
priate measures, reliable and consistent bioinformatic/
biostatistical tools and procedures.
6. Pharmacological treatments
Since the development of effective treatments for mental
disorders 60 years ago, further drug development has con-
centrated on animal models validated using drugs of known
efﬁcacy or relying on resemblance between animal beha-
viours and human psychiatric symptoms. These approaches
have succeeded in improving the tolerability of the proto-
typical psychiatric drugs. However recent years have been
characterised by a paucity of novel drug treatments and
reduced investment in their development, in spite of man-
ifest unmet clinical needs. As we will point out, another
promising approach is to consider compounds as treatments
for speciﬁc symptoms or groups of symptoms (‘symptom
clusters’). When coupled with translational neuroscience
(based on endophenotypes and intermediate phenotypes)
such an approach has the potential to improve the discovery
and validation of novel drug targets as well as provide
biomarkers to stratify patients and realise personalised
psychiatry. The effective use of such strategies will require
increased private-public collaboration and new regulatory
frameworks. Here we summarise some of these issues, point
out gaps in current approaches and strategies required to
address these. The issues are illustrated using the treatment
of schizophrenia and depression as examples.6.1. Deﬁnition
Psychopharmacology studies compounds that affect mental
functions (such as mood and cognition) and behaviour.
Clinical psychopharmacology examines those compounds
that show efﬁcacy in treating mental disorders. As we will
point out, another promising approach is to consider
compounds as treatments for speciﬁc symptoms or groups
of symptoms (‘symptom clusters’). Such an approach has
important implications for both clinical practice and drug
development and regulation.
6.2. Major advances
One of the great advances in psychiatry over the last 60
years has been the establishment of safe and effective
pharmacological treatments for mental disorders. In the
absence of knowledge about underlying neurobiology to
guide rational drug development, treatments for depres-
sion, mania and psychosis were discovered by a combination
of careful clinical observation and serendipity (Lopez-Munoz
et al., 2012). Such treatments are classiﬁed into broad
categories based on their indication such as antidepres-
sants, mood-stabilisers and antipsychotics. The tolerability,
pharmacokinetics and toxicology of the drugs in each class
have been greatly improved by the development of succes-
sive generations of drugs, a process largely based around
the screening of candidate compounds in animal models of
the relevant disorder.
6.3. State of the art
6.3.1. Clinical psychopharmacology
Typically pharmaceutical companies release medications for
diagnoses that are based on observed behaviour and described
symptoms. Psychiatrists deliver pharmacological treatments
according to evidence base and clinical experience, while
tailoring the most probable side-effects to a patient's presenta-
tion (e.g. selecting a more sedating drug for a more agitated
and anxious patient). Certain compounds are indicated for
particular symptoms rather than diagnoses, for example ben-
zodiazepines for (short-term) treatment of anxiety and insom-
nia in the context of many different diagnoses. Others are
indicated for particular disorders, though frequently there is
not a one-to-one correspondence between disorder and drug
response (e.g. the selective serotonin reuptake inhibitor (SSRI)
antidepressants are effective in OCD as well as depression).
Although developments in molecular biology and neuroimaging
provide many candidate biomarkers which may be relevant to
selecting treatment and predicting response, so far there are
only a few circumstances in which biomarkers are clinically
useful to the psychiatrist.
6.3.2. Psychopharmacological drug development
Our initial antipsychotics and antidepressants were developed
without any knowledge of possible targets, based on interesting
behavioural effects in normal rodents (not even animal models
of disease) and excellent clinical observation of their effects in
psychiatric patients by experienced psychiatrists, a type of
phase II study which is largely missing today. Thus, extensive
behavioural pharmacology (preclinical and clinical) was crucial
G. Schumann et al.28for the impressive success of the early years of psychotropic
drug development. More recently drug development has been
based on neurotransmitter hypotheses of psychological dis-
eases. The development of a new psychiatric drug typically
starts with the identiﬁcation of ligands with a high afﬁnity and
selectivity for a molecular target associated with the mechan-
ism of action of the original compounds. Candidate compounds
are then screened in rodent behavioural assays. These assays
were developed and validated using the effects of psychiatric
drugs already known to exert beneﬁt in humans. A compound
demonstrating similar effects to a previously proven one may
then be further developed as a drug of the same class. This
approach has succeeded in improving the tolerability, pharma-
cokinetics and toxicology of the prototypical psychiatric drugs
but has not led to new mechanistic approaches. The most
recent approaches use the development of new targets inde-
pendent of the mechanisms of action of previous compounds.
Examples include antiglutamatergic drugs for schizophrenia and
neurokinin-1 (NK1) antagonists or corticotropin-releasing hor-
mone 1 (CRH1) antagonists for depression and anxiety. In many
cases however, this approach has led to compounds with
inferior efﬁcacy, reducing our hope for new and better
psychotropic drugs arising from our much improved under-
standing of the neurobiology of schizophrenia and depression.
Nevertheless conceptually this approach seems to be most
promising especially when combined with extensive behavioural
observation in animals and patients, a ﬁeld of psychopharma-
cology which has been neglected too much.6.3.3. Neurobiology
In recent years functional neuroimaging has elucidated
cerebral circuits underpinning mental processes disrupted
in psychiatric disorders. At the same time the application of
high-throughput genetic techniques has allowed genome-
wide approaches to examine polymorphisms associated with
psychopathology. The application of such techniques to
traditional nosological entities such as schizophrenia has
led to the discovery of many associated genes of small
effect. It is likely that such entities involve complex gene–
gene and gene–environment interactions and moreover
involve not a single but a variety neurobiological processes
and hence underlying genetics. The current state of the art
is therefore exempliﬁed by convergent approaches combin-
ing neuroimaging with genomics, clinical and neuropsycho-
logical testing and validation in relevant animal models. In
the terms of the NIMH Research Domain Criteria (RDoC)
(Insel et al., 2010), such approaches can be thought of as
probing multiple ‘units of analysis’ for each behaviour or
psychopathology. Such a convergent approach harnesses the
closer correspondence from genotype to brain function than
to clinical diagnosis. It allows the investigation of the
genetic vulnerability and neurobiological underpinning of
psychological traits and their value for predicting the devel-
opment of mental disorders. Moreover it has the potential to
provide novel drug targets, particularly when coupled with a
symptom cluster approach to psychopathology.6.3.4. A translational approach based on symptom
clusters
The symptom cluster approach has the potential to inform
more effective drug development as well as morepersonalised, effective treatment (Tricklebank and Garner,
2012). Common factors, symptom clusters or endophenotypes
can be discerned that are dysfunctional across different
diagnostic categories. An alternative approach to drug dis-
covery would therefore be to examine the neurobiology and
pharmacology of the endophenotypes within these broad
functional domains via translational neuroscience and experi-
mental medicine: the biology of affect (negative and positive
valence), arousal and regulatory systems, social processes and
cognition. In essence, treatments might be developed for
speciﬁc aspects of several diseases, rather than the unrealis-
tic aim of ﬁnding a single treatment for complex multi-
factorial conditions. This also removes the equally unrealistic
requirement for animal models to exhibit the full range of
symptoms encompassed by ICD-10 diagnoses.
This approach is different from disorder-guided treatments
as well as from syndrome-based procedures which is the
historical starting point of psychopharmacology: those were
not founded on biologically validated symptom patterns but
on clinical patterns deﬁned by concurrence of symptoms.
Integrative approaches are therefore needed combining
the assessment of different neurobiological levels under-
lying human behaviour. One example is the Imagen project,
which uses neuropsychological testing, brain imaging and
genetic analysis coupled with pertinent animal models to
examine the constructs of impulsivity, inhibition, attention,
reinforcement sensitivity and novelty seeking (Schumann
et al., 2010b). Identiﬁcation of genetic traits in humans that
inﬂuence the animal phenotype following targeted genetic
mutation would allow investigation of the underlying biol-
ogy and the possible identiﬁcation of new drug targets.
Research that focuses on symptom clusters paves the way
for personalised psychiatry. In this context speciﬁc symp-
toms and symptom clusters can be considered as ‘ﬁnal
common pathways’ emerging from a variety of interindivi-
dual different aetiological and pathogenic pathways: the
goal is to treat a patient's unique symptoms on the basis of
their underlying biology. Genetic variants coding for a
speciﬁc mental disorder are not necessarily more speciﬁc.
Thus, the predisposing genetic pattern of a speciﬁc patient is
likely to be different from the pattern of another patient
with the same ICD-10 diagnosis. Furthermore many genetic
risk factors are found to be common between traditionally
separate disorders, for example the risk variants in the genes
for TCF4, CACNA1c or ANK3 in both schizophrenia and bipolar
disorder (Schizophrenia Psychiatric Genome-Wide Association
Study Consortium, 2011). Coupled with the familial comor-
bidity observed for these disorders, this implies biological
commonality between them, or at least certain symptoms
within them. Investigating the biological dysfunctions respon-
sible for common symptoms may provide novel pharmacolo-
gical targets, and facilitate the development of compounds
indicated for a particular symptom-biomarker proﬁle.6.3.5. Animal models
Animal models, typically in mice, are traditionally tailored
to speciﬁc disorders. Yet, the face validity of these is often
limited. An example is the forced swim test (FST), used as
an indication of antidepressant potential. Rats are placed in
water where they initially demonstrate escape-related
behaviour followed by passive immobile behaviour,
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from active forms of stress coping. In practice many
antidepressant compounds consistently reduce the immobi-
lity time (by increasing escape behaviour) whereas a wide
range of non-antidepressant compounds do not. While
abnormal stress coping is one of the hallmarks of depres-
sion, it is not its deﬁning characteristic. This emphasises the
need to consider discrete aspects of a disorder's symptoms
and aetiology: the FST appears appropriate to investigate
some such aspects of depression while lacking validity for
other core endophenotypes of the syndrome.6.3.6. Biomarkers
A biomarker is an objectively measurable biological variable
used as an indicator of a normal or abnormal biological
process. It is typically a necessary step in a cascade of
changes which produce the symptoms of a disease. It may
indicate vulnerability to a disease, an incipient disease
process, active disease or recovery from a disease. It may
also predict a future disease state or the success or side
effects of treatment. Biomarkers may be useful for mon-
itoring the disease course and treatment. Many biomarkers
have the potential to be reverse translated, i.e. adapted
from humans to animals. This allows more precise validation
of animal models by ensuring they encompass precisely
homologous aspects of disease aetiology, rather than simply
an approximation of symptoms. Furthermore, forward vali-
dation of novel biomarkers discovered in animals may lead
to the discovery of entirely novel disease mechanisms.
Despite these opportunities, biomarker and test-based
deﬁnitions of most psychiatric disorders suffer from the
lack of a ‘biological gold standard’ (Kapur et al., 2012), such
as amyloid plaques and tau tangles for Alzheimer's disease.6.3.7. Examples of the symptom cluster – biomarker
approach
There is preliminary evidence that tailoring antidepressant
treatment to predominant symptoms may improve response
rates and remission. Nutt et al. (2007) note that symptoms
of ‘decreased positive affect’ (including loss of pleasure,
interest and energy) may be better treated by drugs that
enhance noradrenergic and dopaminergic function, whereas
symptoms of ‘increased negative affect’ (including anxiety,
fear and guilt) may respond better to agents that have
noradrenergic and serotonergic activity. While antidepres-
sants show similar efﬁcacy when measured in relation to the
overall syndrome of depression, different drugs show
greater efﬁcacy for the different symptom clusters. Hence
personalising a patient's treatment based on predominant
symptoms could yield increased response and remission
rates. Nutt et al. (2007) further reviewed particular neuro-
transmitters and circuits which may account for these
differences, thus illustrating the general approach of break-
ing down a traditional syndromic diagnosis into symptom
clusters which are individually more neurobiologically tract-
able than the diagnosis as a whole, enabling more targeted
and rational treatment.
Schizophrenia is another example of a traditional noso-
logical entity that is made up of several symptom clusters,
including positive symptoms (psychosis), negative symptoms
(including lack of motivation, poverty of speech and action)and cognitive impairment. Current antipsychotics are
mainly effective in the positive symptom domain but
relatively ineffective for treating cognitive deﬁcits and
negative symptoms (Carpenter and Davis, 2012). Cognitive
deﬁcits are particularly impeding as they compromise
rehabilitation efforts and create barriers to resume employ-
ment. Intense efforts are underway to develop new medica-
tions to address cognitive impairment, making use of new
understanding at the molecular, cellular and circuit level.
The cerebral circuits underlying cognitive function include
loops between frontal lobes, basal ganglia and thalamus as
well as structures underlying contextual memory and fear
conditioning (hippocampal formation and amygdala) (Millan
et al., 2012). Understanding these circuits allows the use of
fMRI of deﬁned brain regions to explore the actions of
putative pro-cognitive agents and validate models.6.4. Questions and problems to be solved
6.4.1. What are beneﬁts, challenges and unmet needs
of currently available psychopharmacological
treatments?
A psychiatrist is unable to predict conﬁdently response to a
medication in an individual patient. For example in schizo-
phrenia or affective disorders 25–40% of patients do not
respond to their ﬁrst prescribed treatment and 10–20% show
clinically signiﬁcant adverse effects (Broich and Möller,
2008). Up to 50–60% of patients fail to respond adequately
to antidepressant therapy (Fava, 2003). In the informative
Sequenced Treatment Alternatives to Relieve Depression
(STARnD) trial only 47% responded to the representative
SSRI citalopram and only 37% achieved a ﬁnal full remission
(Rush et al., 2006). Even after subsequent steps with
alternative and augmentation treatments remission rates
in initial non-remitters remained insufﬁcient (29% in the
second and 16–17% in the third and fourth turns). Thus in
patients with recurrent depression a substantial number do
not achieve remission, even after a sequence of medication
switches and augmentations. These problems may in part be
due to the heterogeneous syndromic nature of depression
coupled with the lack of symptom-speciﬁc indications for
different drugs. Currently there is no way to accurately
predict response to antidepressants. The evidence for the
relative advantages of switching an antidepressant to one of
the same or different class is limited (National Institute for
Health and Clinical Excellence, 2009). Though the SSRIs
represent improved tolerability, side-effects are neverthe-
less a cause of noncompliance with antidepressant therapy
(Papakostas, 2008). Moreover even when treatment is
successful full response does not occur for several weeks
(Gelenberg and Chesen, 2000), lengthening the process of
trialling different treatments and hence lengthening the
time for which a patient is vulnerable to decreased func-
tioning, morbidity and mortality. Current antidepressants
may not be more effective than placebo for patients with
mild depression (Vöhringer and Ghaemi, 2011). While gen-
erally reducing suicide-related behaviour, antidepressants
may cause an increase when used in children and adoles-
cents, leading to warnings issued by the European Medicines
Agency and other regulatory agencies. While there is
growing recognition of a prodrome to depressive episodes
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depressant treatment at this point are unknown. Thus,
taken together, the effectiveness of current antidepressant
therapy is seriously limited.
Similarly low response rates have been reported for
antipsychotic drugs in treating schizophrenia, for example
a meta-analysis by Leucht et al. (2009) found a response
rate to second generation drugs of 41%. Even given three
periods of treatment with antipsychotics from two or more
different chemical classes, up to 20% fail to respond, for
whom the treatment of choice is clozapine (Kane et al.,
1988). However 30% of patients started on clozapine will not
respond (Kerwin, 2005). Antipsychotic polypharmacy is
often resorted to in such clozapine-resistant patients, a
practice with little evidence base and increased risk of side-
effects (Taylor, 2010a). These problems are compounded by
the current impossibility of predicting which patients will
respond to antipsychotic treatment. For patients who do
respond full remission is unusual. Taking remission as the
ultimate aim of treatment, the majority of schizophrenia
cases are ‘treatment-resistant’. Furthermore current anti-
psychotic drugs are ineffective in addressing negative
symptoms (blunted affect, alogia, lack of motivation and
social interaction) and cognitive impairment. This highlights
the fact that schizophrenia is a syndrome made up of
several symptom clusters, for which we lack symptom-
speciﬁc drugs.
Retrospective studies clearly demonstrate a reverse
relationship between length of untreated psychosis and
degree of treatment success suggesting early recognition
and treatment (Marshall et al., 2005). Beyond effectively
treating schizophrenia, a more desirable goal would be to
achieve prevention by starting treatment during the pro-
dromal phase, seeking to prevent conversion to full psycho-
sis. Early detection and treatment appears in the long term
(15 years) to augment functioning, to increase recovery
rates and to reduce the remaining deﬁcits (ten Velden
Hegelstad et al., 2012). However current antipsychotic
drugs have not convincingly been shown to reduce conver-
sion rates (McGlashan et al., 2006).
The urgent need for novel antidepressants and antipsy-
chotics is widely recognised (e.g. Murrough and Charney,
2012). Although optimising currently used paradigms for
drug development is one approach (e.g. triple reuptake
inhibitors as antidepressants) only new mechanisms of
action have the potential to overcome the actual barriers
of effectiveness. In this vein preferentially glutamatergic
substances are being explored for efﬁcacy in affective as
well as psychotic disorders. The driving forces of this
innovative development have been model systems revealing
the crucial role of the glutamatergic system.6.4.2. What are the most important patient related
outcomes?
Two components of treatment outcome are currently used:
(a) symptom patterns and their severity, deﬁning the global
concepts of remission and recovery; (b) everyday functioning
as well as participation in social activities and professional
employment. Both aspects (a) and (b) are only partly
correlated. Employment status is particularly relevant in
the long term, whereas symptom remission is the main focusof RCTs designed for acute treatments. There is a growing
trend towards including long term functional outcome in the
assessment of treatments (e.g. NICE estimating beneﬁt-risk
ratios). Major international efforts are currently establishing
new comprehensive tools to measure Personal and Social
Performance and Skills (Figueira and Brissos, 2011).
Both aspects (a) and (b) can be measured either by
observer as well as by patients themselves (self-assess-
ment). Outcomes of treatment as judged by patients
themselves have acquired increasing importance in psychia-
try. The use of such measures rightly places patients at the
centre of their care as consumers rather than passive
subjects of mental health services. Moreover they capture
aspects of mental wellbeing that may not be evident in
objective assessment.
Recovery and quality of life have been identiﬁed as
important patient related outcomes, beyond symptom
remission. Improvements in such outcomes related to every-
day functioning and wellbeing rated by patients may not
correlate with psychiatric symptoms as rated by clinicians
(Fleischhacker et al., 2005). Oorschot et al. (2012) found
that symptom remission status was not related to functional
recovery in schizophrenia. Yet the application of such
concepts to assessing treatments for mental disorders is
complicated by the lack of consistent deﬁnitions (Leucht
and Lasser, 2006; Katschnig, 2006).6.4.3. How can advances in understanding the
functional circuitry supporting cognition, mentalizing,
perception, behaviour and emotions inform the search
for new therapeutic targets?
Alterations in such functional circuitry underlie mental
disorders (Insel, 2010). Coupled with the symptom cluster
approach described above, understanding these alterations
will allow selection of more informative animal models
based on their showing similar altered functional circuitry.
This avoids the circularity of models based on response to
agents of known efﬁcacy, which are less likely to provide
truly new therapeutic targets. Furthermore models based
on functional circuitry have higher construct validity than
those based on comparing rodent and human behaviour,
which rely on face validity. Such face validity is sometimes
questionable or impossible. For example while rodents
certainly display social cognition, some aspects which are
highly developed in humans such as theory of mind and
language do not have sufﬁcient correspondence to allow
easy development of valid models.
Conversely other cognitive domains such as working
memory and episodic memory are based on functional
circuitry that appears to be relatively conserved between
different mammals. Such circuitry includes loops between
frontal lobe, basal ganglia and thalamus as well as hippo-
campal and other territories (Millan et al., 2012). Notably
working and episodic memory are impaired in schizophrenia
and may constitute endophenotypes marking increased risk
of developing the disorder. Hence they are examples of
cognitive domains where valid translational models are
possible and important. Such models are instrumental to
initiatives seeking to improve the search for new therapeutic
targets, for example CNTRICS (Cognitive Neuroscience-Based
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Cognition in Schizophrenia) (Carter and Barch, 2007).
Anhedonia is anotherexampleofapsychiatric symptomthat
is core tomental disorders including schizophrenia and depres-
sion where advances in understanding functional circuitry will
provide models with better construct and predictive validity.
Traditional models relying on face validity involve anhedonia-
like rodent behaviour such as reduced sweet solution prefer-
ence. However ﬁndings correlating anhedonia with decreased
nucleus accumbens (Nac) activation in response to reward,
decreasedNacvolumeanddecreased rostral anterior cingulate
cortex resting activity point to underlying functional circuitry
that can be assessed by such translational measures (Wacker
et al., 2009). These measures can be used to assess models
based on construct rather than face validity, similarly enhan-
cing the search for new therapeutic targets.6.4.4. What is the relationship to neurotransmitter
based pharmacology?
Mental disorders emerge from altered functional brain
circuits. Yet currently available drugs do not directly target
functional circuitry per se. They are designed as ligands to
neurotransmitter transporters and/or receptors involved in
neuronal signalling, the functional basis of all circuit loops.
However as a speciﬁc receptor or transporter for a speciﬁc
neurotransmitter is likely to be involved in a very large
number of brain circuits widely distributed in the brain
those treatment approaches are insufﬁciently focussed.
Furthermore multiple neurotransmitter systems modulate
a speciﬁc circuitry. For example the circuitry underling
working memory involves many different interacting neuro-
transmitters whose roles are increasingly understood. These
include interaction between glutamate NMDA and dopamine
D1 receptors in circuitry linking prefrontal and other
cortical areas implicated in the maintenance of sensory
information crucial for working memory (Castner and
Williams, 2007). Knowing which receptors are involved
implicates drug classes acting on those receptors, however
the relationship between a receptor effect and efﬁcacy may
not be simple. In the case of D1 receptor function there is
evidence of an ‘inverted-U’ response curve (Williams and
Castner, 2006). Knowledge of such a relationship in a
speciﬁc circuit suggests prototypes for pharmacological
modulators of that circuit; it further allows the prediction
that careful titration of a putative drug may be required to
achieve therapeutic response.
In the case of anhedonia, the Nac and prefrontal cortex
are linked by the mesocorticolimbic dopaminergic pathway.
It is therefore rational to use antidepressants that enhance
dopamine release to treat cases of depression where dimin-
ished pleasure is predominant. This is an example of the
clinical relevance of combining a symptom cluster approach
with understanding of the neurotransmitters involved in
relevant functional circuitry, and forms part of the rationale
behind delineating a subtype of depression dominated by
reduced positive affect that is inadequately addressed by
serotonergic antidepressants (Nutt et al., 2007).
The most recent advances in preclinical depression
research involve the characterisation of multiple circuit-
related symptom clusters using emergent techniques includ-
ing optogenetics as well as functional imaging,neurophysiology and genomics (Berton et al., 2012). These
promise the possibility of more valid models for drug
discovery and novel therapeutic targets.6.4.5. How can molecular genetic and epigenetic
discoveries inform drug and biomarker development?
The high heritability of psychiatric disorders suggests that
certain genetic variants convey increased risk. Such variants
might be used as biomarkers to stratify patients. It is also
evident that genetic variants have a bearing on pharmaco-
kinetics, due to their effect on metabolising enzymes, as
well as pharmacodynamics by affecting targeted receptor
systems. Hence it is reasonable to expect that genetic
biomarkers should predict treatment response. Moreover
studying the functional signiﬁcance of such variants should
shed light on the pathophysiology of mental disorders and
lead to new therapeutic targets. This line of development
has already turned out to be very successful in monogenic
mental disorders. For example Fragile X syndrome is caused
by mutations in the FRM-1-gene on the X chromosome. This
most commonly occurring X chromosome related mental
retardation was until recently considered to be untreatable.
The functional consequence of the underlying FRM-1 gene
mutation is a reduced repression of metabotropic glutamate
receptor expression during development resulting in mental
retardation, autistic behaviour and somatic malformations.
Based on these insights which emerged from 20 years of
intensive research (particularly in animal model systems) a
metabotropic glutamate-receptor-antagonist currently demon-
strates cognitive enhancing effects in clinical trials in Fragile X
boys (Hovelsø et al., 2012).
Genetic discoveries have the potential to inform the
development of more valid animal models. These include
mouse models carrying humanised mutations or engineered
deletions or insertions. One example is the 22q11.2 deletion
syndrome (which confers a 20% risk of schizophrenia) and
the corresponding model of Df(16)A+/ mice. The Novel
Methods leading to New Medications in Depression and
Schizophrenia (NEWMEDS, 2013) project has made use of
this model to understand the pathophysiology of schizo-
phrenia. Genetic, anatomical and behavioural measures are
taken in schizophrenic and non-schizophrenic individuals
with 22q11.2 deletion as well as translational measures in
the Df(16)A+/ mice. Preliminary results suggest that the
animals have deﬁcits in spatial memory and a loss of
hippocampal-frontal synchrony. By administrating tests that
are known to engage these regions in both mice and
individuals with the deletion the human to mouse genetic
translation is tested. Similarities will provide a framework
for investigating the pathophysiology and symptoms induced
by the manipulation. Where the symptoms are relevant to
schizophrenia (or other neurodevelopment disorders), the
animals and human carriers will provide the means to
investigate the biology underlying these symptoms and
search for new pharmacological targets.
Epigenetic factors including DNA methylation and histone
modiﬁcation inﬂuence psychiatric disease phenotypes. They
are likely to be among the mechanisms by which early life
adversity increases disease risk in adulthood and they offer
novel drug targets and additional ways of validating models.
For example Covington et al. (2009) found changes in
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depressed humans and mice exposed to chronic social
defeat stress. They demonstrated that a histone deacety-
lase inhibitor exerted antidepressant effects and reversed
the effects of social defeat stress on gene expression in the
nucleus accumbens, pointing to the potential of such
compounds as novel antidepressant agents.
6.4.6. Which measures of speciﬁc phenotypes and/or
associated functions can serve as outcome measures or
biomarkers?
Biomarkers may be used as measures of treatment response
and outcome. Where a biomarker is correlated with a
relevant clinical endpoint it may be used as a surrogate
endpoint. A clinical endpoint measures how a patient feels,
functions or survives and a surrogate endpoint is a biomar-
ker that can substitute for this (Biomarkers Deﬁnition
Working Group, 2001). Surrogate endpoints for psychiatric
drug development will become more evident with increas-
ing understanding of pathophysiology. Examples include
functional brain imaging of relevant regions, such as pre-
frontal cortex and hippocampus in the case of cognitive
impairment in schizophrenia.
6.4.7. What is the role of the environment?
Mental disorders represent the ﬁnal common pathway of
diverse pathophysiologies involving environmental as well as
genetic contributions. For example schizophrenia is asso-
ciated with environmental insults during late embryonic
gestation. Knowledge of such environmental factors informs
the development of valid animal models. These include the
MAM E17 rat model of schizophrenia which involves the
administration of the DNA-alkylating agent methylazoxy-
methanol acetate (MAM) on embryonic day 17, producing a
pattern of neurodevelopmental and behavioural effects that
bear similarity to some aspects of schizophrenia (Moore
et al., 2006). However ascribing construct validity to such a
model must be tempered by the knowledge that schizo-
phrenia does not arise from a sudden transient inhibition of
embryonic mitosis, such as that induced by MAM. A closer ﬁt
to the aetiology of schizophrenia might be provided by my a
model that involves a genetic predisposition coupled with
an environmental insult, such as the complexin2 knockout
mouse in which schizophrenia-like behaviour manifests
following a mild parietal lesion during puberty (Radyushkin
et al., 2010). However neither of these models accurately
mirrors the complex and subtle gene–environment interac-
tions of schizophrenia, which remains a challenge for future
model development.
6.4.8. What are the consequences for drug trials,
industry–academia interaction and regulatory activities?
Pharmaceutical companies that formerly developed new
treatments have cut resources devoted to neuroscience
research. Reasons cited include the subjective nature of
endpoints in psychiatry making it difﬁcult to demonstrate
efﬁcacy even after large scale trials. In addition psycho-
pharmaceutical development cycles are relatively costly
and often fail at a late stage. This ‘attrition’ results in a
situation where each psychiatric drug marketed must pro-
vide enough proﬁt to recoup the losses incurred by tenother failed compounds, a situation many companies ﬁnd
unsupportable. The rational use of more valid animal
models based on translational neuroscience will allow ear-
lier ‘go/no go’ decisions to be made about candidate
compounds leading to more economical and successful drug
development. Industry-academia collaboration will be cru-
cial as the variety of techniques and resources required is
beyond the capabilities of any one organisation.
6.5. Gaps and needs
6.5.1. More valid animal models
These may be based on translated biomarkers of disease
processes reverse translated from humans. Increased knowl-
edge of the underlying biology of mental disorders will allow
models based on endophenotypes and intermediate pheno-
types, having greater construct validity than previous
models based on superﬁcial resemblance to human psycho-
pathology (face validity). While rodent models have domi-
nated drug development, there is need for a cross-species
approach including non-mammalian models as appropriate
for each unit of analysis. It would be desirable to have
models that recapitulate gene–environment interactions
and model disease development rather than approximating
ultimate symptoms in affected humans in order to develop
treatments effective for early intervention.
6.5.2. Predictive clinical biomarkers
There is a need for biomarkers that can be used to stratify
patients based on risk, prognosis and predicted treatment
response. These will be based on increased knowledge of
the biology of mental disorders and may arise from forward
translations of biomarkers from animal models.
6.5.3. Convergence of methods
Different translational tools are complementary and must
be integrated across units of analysis to provide novel
biomarkers, endophenotypes and intermediate phenotypes.
Examples include relating altered functional connectivity as
measured using fMRI with genetic ﬁndings to yield a systems
view of genetic risk architecture. Within neuroimaging,
efforts to integrate EEG/MEG (high temporal resolution)
with fMRI (high spatial resolution) are expected to be
increasing applied to psychiatric disorders. Another exam-
ple is the development of a prototype MRI/PET scanner for
human and rodent brains to acquire structural and mole-
cular functional data simultaneously.
6.5.4. Collaboration between organisations
The convergent translational approach described here requires
a range of expertise and capabilities that lies beyond any
single commercial or academic organisation. It requires coop-
eration that is incompatible with the traditional closed and
secretive approach to drug development. Thus there is a need
for further public–private projects such as the European
Innovative Medicines Initiative (IMI), as well as further coopera-
tion between laboratories specialising in different methods.
6.5.5. New regulatory frameworks
The European Medicines Agency has constructed a qualiﬁca-
tion procedure for biomarkers in drug development. There
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include, for example, the targeting of symptom clusters
such as impulsivity in substance misuse and attention deﬁcit
hyperactivity disorder.
6.5.6. New genetic tools to shed light on the ‘dark
matter’ of psychiatric genetics
The unaccounted heritability of psychiatric disorders likely
includes rare copy number variations or point mutations, or
single nucleotide polymorphisms in exons. Exome and whole
genome sequencing techniques are predicted to lead to the
discovery of further moderate and high risk mutations,
increasing understanding of underlying neurobiology and
providing novel drug targets.
6.5.7. The application of novel basic cellular and
molecular techniques to drug target discovery and drug
development
These include optogenetic methods which allow the mea-
surement of activations in different neural cell types with
high temporal resolution in transgenic animals carrying
psychiatric risk genes, which may provide novel means for
target validation. Another promising ﬁeld is induced plur-
ipotent stem (iPS) cell technology, potentially allowing the
modelling of psychiatric disorders in cultured neurons.
7. Psychiatric somatic comorbidity
Comorbidity between psychiatric and somatic disorders is
more a rule than an exception, and patients with severe
mental disorders have a 2–3 fold excess mortality compared
to the general population, half of this excess being caused
by physical disorders. Comorbidity may be explained by
many psycho-social and environmental factors, but can also
be related to a common biological disease pathology or
aetiology. In this paper we have described some major
psychiatric disorders in relation to comorbid somatic dis-
orders. We propose allostatic load as an overarching theory
to explain causal relations for comorbidities, and that
systematically related research questions should focus on
epigenetic, inﬂammatory or neuroendocrine pathways as
possible mediators of shared/joint aetiology. In addition,
studies aiming at entangling the pharmacogenetics of
efﬁcacy and safety need to focus on comorbidity proﬁles
in order to develop new insights into disease pathophysiol-
ogy and to reduce the risk of pharmacogenically induced
somatic diseases. We also point to negative comorbidity as an
understudied, potentially valuable model, for investigating
biological relations between psychiatric and somatic disor-
ders. A greater understanding of the associations between
clinical constellations of symptoms from both psychiatric and
somatic disorders as they develop over time and relate to
genetic, epigenetic, biochemical, cellular, neurophysiologi-
cal, morphological or other biological markers is needed.
From a biomedical perspective there is a need to establish a
collaborative network of scientists to combine expertise in
clinical, pharmacological, molecular and genetic methodol-
ogy, and to set up a large clinical cohort that can be
prospectively followed with a series of emerging biological
markers as the clinical picture of psychiatric and somatic
symptom manifestations develops over time.7.1. Deﬁnition
The term ‘comorbidity’ was established in medicine by
Feinstein (1970) to designate those cases in which a ‘distinct
additional clinical entity’ occurred during the clinical course
of a patient having an index disease. The concurrent presence
of several pathological conditions in the form of comorbidity
and multimorbidity is more a rule than an exception in all
populations of patients. Comorbidity can be explained by
many factors, such as modiﬁable lifestyle issues, side effects
from medications, insufﬁcient health care, but may also be
related to a common disease pathogenesis or aetiology. The
well described comorbidity of psychiatric disorders and
somatic diseases may be used to identify existing gaps in
our knowledge to deﬁne targets for future research.
7.2. State of the art
A recent review conducted as part of the World Psychiatric
Association Action Plan 2008–2011 demonstrated a 2–3 fold
excess mortality in patients with severe mental disorders,
compared to the general population. They found that the
mortality gap was mainly due to physical illness and, that
this gap seems to have increased in recent decades, even in
countries where the quality of the health care system is
commonly recognised to be good (De Hert et al., 2011).
Several factors and theories are used to explain comorbid-
ity of mental disorders and somatic diseases including shared
predispositions (genetic, temperamental and personality
traits), shared risk factors (stress, trauma, food intolerance,
life styles, social support, negative emotions) or, shared
mechanisms (coping, resilience or defence mechanisms,
endocrine and immune disruption) (Jakovljević et al., 2010).
The anticipation is that a better understanding of
psychiatric-somatic comorbidity in combination with increas-
ingly advanced methods of neurobiological research will
contribute to provide (1) descriptions of systemic clinical
manifestations of psychiatric phenotypes, (2) sub- (or even)
endophenotypes for genetic research based on co-occurring
somatic and psychiatric symptoms, (3) a better understand-
ing of the biological pathomechanisms of psychiatric dis-
orders and somatic diseases, and (4) improved understanding
of biological treatment mechanisms, including its potential
for harmful side effects, and the detection of new targets for
psychopharmacological treatment interventions.
7.3. Major advances
7.3.1. The somatic comorbidity of schizophrenia and
bipolar disorder
It is commonly accepted that both schizophrenia and bipolar
disorder have an increased risk of developing somatic
diseases, and higher mortality rates in comparison with
the general population (De Hert et al., 2011). A review
including 15 original research articles on somatic co-
morbidity in patients suffering from psychotic disorders
concluded that these patients run a substantial risk of
developing diabetes mellitus, metabolic syndrome, hyper-
tension, cardiovascular diseases, lung diseases such as
COPD, hypothyroidism and visual problems (Oud and
Meyboom-de Jong, 2009). A recent population-based cohort
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chronic diseases on excess mortality due to diseases and
medical conditions (natural death) in individuals with
schizophrenia and bipolar disorder found that somatic
diseases accounted for half of the excess mortality
(Laursen et al., 2011). Furthermore, almost all somatic
chronic disorders investigated in this study were more
frequent in schizophrenia and bipolar disorder than in the
general population. The only somatic disorder with a lower
prevalence in psychotic patients was connective tissue
disease, mainly rheumatoid arthritis (with symptoms of
musculoskeletal pain). According to a recent study compar-
ing the prevalence of somatic comorbidity in a clinical
sample of patients with bipolar disorder and schizophrenia,
somatic comorbidity appears to be more frequent in bipolar
patients than in schizophrenia (67.1% vs. 50.6%). (Oreški
et al., 2012). Whereas rheumatoid arthritis is less prevalent
in schizophrenia compared to the general population this is
not the case in bipolar disorder (Mors et al., 1999). Con-
versely, ﬁbromyalgia is more prevalent in bipolar disorder but
not in schizophrenia (Wilke et al., 2010). Interestingly,
several studies have also found a signiﬁcantly lower risk of
respiratory and prostate cancer in people with schizophrenia
(Tabarés-Seisdedos et al., 2009). Some studies indicate
cardiovascular disease is “truly” more prevalent in bipolar
disorder, whereas it in schizophrenia most likely is secondary
to atypical antipsychotic medications and smoking (Osby
et al., 2001). There is however also emerging evidence of a
shared genetic basis for schizophrenia and at least some
cardiovascular disease risk factors (Andreassen et al., 2013).7.3.2. Physical health in patients with depressive
disorders
There is evidence that patients with affective disorders
suffer from greater physical morbidity and mortality than
the general population (Vieta and Colom, 2011). Mortality
rate is approximately twice that of the general population
with suicide mortality being up to 20 times higher (Osby
et al., 2001). The relationship between affective disorders
and physical illness is reciprocal: many chronic illnesses
cause higher rates of depression and affective symptoms
have been shown to forerun many chronic diseases and
worsen their outcomes (Kupfer et al., 2012). People suffering
from chronic illnesses are almost three times more likely to
be depressed (Egede, 2007), and having two or more chronic
illnesses increases the risk of being depressed to up to seven
times that of healthy subjects (3.2% vs 23%) (Moussavi et al.,
2007). Moreover, depression is associated with a decrement
in health signiﬁcantly higher than those associated with other
chronic diseases (Moussavi et al., 2007). This includes
increasing illness-related morbidity and mortality and decre-
ment in functional outcomes, such as disability and decline in
health-related quality of life (Kupfer et al., 2012).
Depression can also precede physical disease and act as a
risk factor. It has been shown to act as a predictor to
coronary heart disease (Kendler et al., 2009), stroke
(Everson et al., 1998), obesity and metabolic syndrome
(Luppino et al., 2010), diabetes (Campayo et al., 2010a,
2010b) colorectal cancer, back pain, irritable bowel syn-
drome, multiple sclerosis and infant stunting and death if
depression occurs during pregnancy (Goldberg, 2010).The association between affective disorders and a higher
prevalence of physical morbidity and mortality can be
partially explained by considering health behaviours (e.g.
smoking, physical inactivity, poor diet), psychosocial func-
tioning and chronic medication exposure (Leboyer et al.,
2012). However, this association remains signiﬁcant after
controlling for these confounding factors, which suggests
additional and speciﬁc mechanisms (Leboyer et al., 2012)
(Krishnadas and Cavanagh, 2012).7.3.3. Anxiety disorders and physical illness
Comorbidity between anxiety disorders and physical illness is a
limited but expanding area of the scientiﬁc literature. Several
studies relying onclinical or epidemiologic samples have shown
higher rates of medical illnesses among patients with anxiety
disorders compared to controls (Rogers et al., 1994). Clinical
and community studies have also reported an association of
physical illness with anxiety disorders as strong as or stronger
than that with mood disorders (McWilliams et al., 2004).
Studies examining associations with speciﬁc illnesses, such
as thyroid disease, cancer, diabetes, cardiac disease, gastro-
intestinal disease, respiratory disease, and chronic pain, have
found levels of anxiety disorders among patients seeking
treatment for medical conditions to be higher than expected
compared to the general population (Härter et al., 2003).
Data on comorbidity according to speciﬁc subtypes of anxiety
andmedical illness reveal that theassociation is greater forpanic
disorderandgeneralisedanxietystates thanforphobias.Patients
with panic disorder are more likely to have speciﬁc comorbid
medical disorders such as angina, mitral valve prolapse, idio-
pathic cardiomyopathy, labile hypertension, respiratory ill-
nesses, migraine headaches, peptic ulcer disease, diabetes
mellitus, or thyroid disease (Rogers et al., 1994). With the
publication of DSM-IV, individuals could receive a diagnosis of
PTSD as a direct result of being traumatised by the experience of
a life-threatening illness. This development has contributed to
an interest in the association between PTSD and physical illness.
Among DSM-IV anxiety disorders, PTSD had the greatest number
of signiﬁcant associationswith chronic physical disorders, includ-
ing neurological, cardiovascular, gastrointestinal, metabolic/
autoimmune, and bone or joint conditions (Sareen et al., 2005).7.3.4. Alcohol use disorders and comorbid somatic
disorders
Clinical experience supports the evidence that somatic
disorders are frequent in subjects with alcohol use disorders.
An important proportion of cases of cancer can be attributed
to alcohol consumption and in a recent study from Western
Europe one in 10 of all cancers in men and one in 33 in
women were caused by past or current alcohol intake
(Schütze et al., 2011). Depending on the sample investi-
gated, the rates of somatic disorders as a consequence of
chronic and pathological alcohol use vary. Further, since
alcohol is widely distributed in the human body, several
tissues and organ systems can be affected by the toxicity of
alcohol. Most frequently investigated are alcohol-associated
liver and pancreatic diseases, followed by malignant tumours
and disorders of the central and peripheral nervous system.
Earlier epidemiological data of more than 10,000 inpa-
tients from the U.S. demonstrated that more than 70% of
the alcohol-dependent men and 73% of the women had a
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1986). The most prevalent disorders among them were
diseases of the liver, gallbladder and pancreas; bronchitis;
emphysema; and asthma. Hypertensive disease was found in
15% of the men and 7% of the women.
Signiﬁcant comorbidity was also detected in European
samples. In alcohol-dependent subjects in inpatient detox-
iﬁcation treatment, a Polish study reported a rate of almost
44% of alcohol-related liver disease (Kroch et al., 2004).
5.2% of the patients had pancreatitis and suffered from
hepatitis B. Approximately 1/3 of the sample had diabetes
and cardiovascular diseases. 55 patients (12.4%) had a
history of severe head trauma, and 51 (11.3%) were treated
for “multiorgan trauma”. In addition, comorbidity with
other mental disorders was high. 102 patients (23%)
reported affective disorders, and in 92 (20.7%) personality
disorders were diagnosed.7.3.5. Medication related somatic disorders
Psychotropic drugs have proven to compare favourably with
medications used in other ﬁelds of medicine with regards to
effective clinical disease control (Leucht et al., 2012).
However, the optimal use of the psychotropics is often
hampered by adverse effects, some of which can develop
into treatment-emergent comorbid medical conditions. As
opposed to psychopharmacology-associated acute medical
reactions such as sudden cardiac death or malignant neu-
roleptic syndrome that are dramatic but rare, there are
several delayed or chronic somatic disorders that are rather
frequent. Examples include lithium-induced thyroid dys-
functions (Lazarus, 2009); valproate-associated hormonal
dysregulations and the polycystic ovary syndrome (Hu et al.,
2011); antipsychotic-induced weight gain and adverse meta-
bolic inﬂuences (De Hert et al., 2009), hyperprolactinemia
(Cookson et al., 2012) and movement disorders (Dayalu and
Chou, 2008). The different somatic disorders are generally
not restricted to one particular group of psychotropics. For
example mood-stabilizers, antidepressants and antipsycho-
tics all share propensities for inducing weight gain. This
point is important as the concomitant use of several drugs is
common in clinical practice, which increases the risk of
additive or even potentiated adverse somatic effects
(Fleischhacker and Uchida, 2012).
Metabolic drug effects have received particular attention
in recent years as patients with severe mental disorders have
a high degree of glucose and lipid regulation disturbances
(Fleischhacker et al., 2008) believed to contribute signiﬁ-
cantly to a reduced life-expectancy of about 25 years
compared to the general population (Tiihonen et al.,
2009), and cardiovascular diseases account for the majority
of these premature deaths (De Hert et al., 2009). Psycho-
tropics, and antipsychotics in particular, are prone to
adversely inﬂuence several of the components of metabolic
health although the mechanisms are only fragmentarily
known. Differential propensities among antipsychotic drugs
for inducing weight gain and other metabolic disturbances
have been found in recent meta-analyses of clinical trials
(Rummel-Kluge et al., 2010), with clozapine and olanzapine
being the most prominent offenders.
Although movement disorders have become much less of
a clinical problem since the introduction of new generationantipsychotics, a certain risk of acute and tardive motor
adverse effects remains. Of these, tardive dyskinesia is by
far the most worrisome, as in contrast to acute dystonia,
parkinsonism or akathisia, an appreciable percentage of
tardive dyskinesia does not respond to treatment and may
turn into a chronic comorbidity (Dayalu and Chou, 2008).
Most of the adverse events exempliﬁed above are rela-
tively easy to either prevent or manage. A pre-requisite to
reduce the risk of psychotropic induced comorbidity there-
fore lies in the awareness of such side effects and the regular
monitoring of a respective drug's safety and tolerability.7.3.6. Conclusion
In summary, many physical disorders have been identiﬁed that
are associated with severe mental health disorders and alcohol
abuse, and medical disorders account for more than half of
the excess mortality found in these patients. The increased
somatic comorbidity is due to many factors such as side-
effects of pharmacological treatment, unhealthy diet, and
high levels of cigarette smoking, as well as inadequate medical
treatment or provision of health care. However, a better
understanding of comorbidity and multimorbidity also carries
the potential of developing new insights into the biological
underpinnings of both psychiatric disorders and somatic dis-
eases, and improving the treatment in these patients.7.4. Questions and problems to be solved
7.4.1. Allostatic load in relation to comorbidity
There is an overarching need to better understand the
causal relation between comorbid diseases. Allostatic load
refers to the “cost of chronic exposure to ﬂuctuating or
heightened neural or neuroendocrine response resulting
from repeated or chronic environmental challenge that an
individual reacts to as being particularly stressful” (McEwen
and Stellar, 1993). Allostatic load is highly relevant in
comorbidity studies as it is associated with oxidative and
nitrosative stress, mitochondrial dysfunction, inﬂammation
and lowering of neuroprotective factors, which relate to
impaired immunity, atherosclerosis, apoptosis and atrophy
of nerve cells in the brain. We propose allostatic load as an
overarching theory of shared/joint aetiology and a model to
explain causal relations between comorbidities. The con-
duits for allostatic load may be epigenetic, inﬂammatory or
neuroendocrine, and the different pathways mediating this
relation should be targets for a large number of system-
atically related research questions7.4.2. Epigenetics of multimorbidity and comorbidity
Several common somatic and psychiatric diseases may be
caused by epigenetic dysregulation, and this has been
emphasised for schizophrenia, bipolar disorder, depression,
post-traumatic stress disorder, diabetes, cancer, coronary
heart disease, etc., and epigenetic inﬂuences from present
or previous life events or exposures may be responsible for
the vast variation in the presentation and clinical outcome
of disease and disease comorbidity. Future studies on
epigenetic changes open new opportunities in understand-
ing the pathophysiology of the comorbidity between mental
and somatic disorders.
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comorbidity
Inﬂammation seems to be an omnipresent pathomechanism
in many diseases including cardiovascular disease, diabetes,
cancer, bipolar disorder and schizophrenia, and over the last
decades, there has been increasing evidence that inﬂamma-
tion may be implicated in the pathophysiology of affective
disorders, sharing common pathways with physical illness.
Studies of epigenetic regulation of the inﬂammatory response
systems may reveal a molecular basis for the frequently
occurring phenomenon of comorbidity and multimorbidity.
7.4.4. Stress and the HPA axis and comorbidity
The HPA axis is involved in the neurobiology of mood
disorders and functional illnesses, including anxiety disorder,
bipolar disorder, insomnia, post-traumatic stress disorder,
borderline personality disorder, ADHD, major depressive
disorder, burnout, chronic fatigue syndrome, ﬁbromyalgia,
irritable bowel syndrome, and alcoholism. The HPA axis can
be activated both through social as well as physical stressors,
and the different pathways involve the monoamines dopa-
mine, noradrenaline and serotonin, and could explain how
mental and physical disorders interact in a comorbid manner.
7.4.5. Pharmacogenetics and comorbidity
Large inter-individual differences exist with respect to
safety of psychotropics. The major inter-individual variability
in susceptibility to adverse effects points to genetic media-
tors and modiﬁers of a drug's effects. Pharmacogenetic
approaches have thus far not provided a breakthrough of
relevance to clinical psychopharmacology although promising
results have been reported. Studies aiming at entangling the
pharmacogenetics of the adverse drug effects, as well as the
complex gene–environment interactions are needed using the
steadily evolving new techniques, thus providing a basis for
personalised medicine with individually tailored drug regi-
mens based on personal comorbidity proﬁles.
7.4.6. Negative comorbidity
In contrast to co-occurrence, few population based studies
have explored in detail the “negative” or “inverse” comor-
bidity in psychiatric and somatic disorders (Tabarés-Seisdedos
et al., 2009). It is interesting that two population based
studies and a metaanalysis of cancer incidence rates found a
signiﬁcantly lower risk of respiratory and prostate cancer in
people with schizophrenia after adjusting for confounding
variables, as this is the opposite of what would be expected
from what is known about general risk factors in these
patients. Furthermore, it is intriguing that a reduced occur-
rence of rheumatoid arthritis has been found in patients with
schizophrenia. Negative comorbidity may be a valuable
model for investigating common or related pathways in the
effort of understanding the biological relations between
psychiatric and somatic disorders.
7.5. Gaps
Despite existing knowledge about the high frequency and
severe consequences of somatic comorbidity in patientswith mental disorders, the mortality gap between psychia-
tric patients and the population seems to be increasing.
Although it is well known that many psychosocial factors
like lack of social support, negative lifestyle habits, inade-
quate health care and awareness, the potential biological
mechanisms (including psychopharmacologically induced
somatic disorders) underpinnings of those comorbidities
are far from well understood. A greater understanding of
the associations between clinical constellations of symp-
toms of both psychiatric and somatic disorders as they
develop over time and relate to genetic, epigenetic,
biochemical, cellular, neurophysiological, morphological or
other biological markers is needed. At present, much of the
existing information stems from cross-sectional studies,
epidemiological studies with inaccurate clinical diagnosis
or from clinical studies of patient cohorts afﬂicted by
Berkson's bias or with insufﬁcient clinical or biological
information.
7.6. Needs
There is an immediate need to establish new research that
can contribute to diminishing the mortality gap and nega-
tive health impact, caused by physical disease in patients
with mental health disorders. From a biomedical perspec-
tive there is need to establish a collaborative network of
scientists to combine expertise in clinical, pharmacological,
molecular and genetic methodology, and to set up a large
clinical cohort that can be prospectively followed with a
series of emerging biological markers as the clinical picture
of psychiatric and somatic symptom manifestations devel-
ops over time, in order to determine the biological under-
pinning of the important phenomenon of psychiatric-
somatic comorbidity.
8. Consensus discussion
In the preceding statements the experts identiﬁed more
than 50 gaps and advances needed, which are of signiﬁcant
effectiveness, impact and feasibility to add to European
research strength. However, in order to appropriately rank
the suggestions from various research domains, relevant
overarching criteria, which are intrinsic to mental health
research, and in particular biomedical research, are essen-
tial. Among the members and experts of the Workpackage
on Biomedical Research (WP4) of ROAMER the overarching
criterion was identiﬁed as being the effort to strive to
reduce illness and improve mental health, reduce suffering
and increase well being, and decrease the economical
burden of mental disorders.
The expert recommendations proposed by this workpack-
age will now be considered and ranked by members of the
ROAMER consortium, by the scientiﬁc community as well as
by stakeholder groups. Their likely costs and chances of
impact on mental health burdens and the European agenda
of competitiveness, growth and jobs will be assessed. The
ﬁnal recommendations made by ROAMER will balance the
priority levels of each of the potential gaps in research
identiﬁed across all work packages. Thus the
37Medicine for mental disordersrecommendations made in this article do not represent
ofﬁcial ROAMER consortium statements but contribute to its
comprehensive and participatory approach.
While it is necessary to identify gaps and advances, which
characterise (1) areas of discovery, it is equally important to
establish (2) the structural (and infrastructural) gaps and
advances needed to achieve the discovery goals.(1) To determine the areas most relevant for discovery,
assessment of psychopathological burden across the
lifespan, as well as in various environmental conditions
is a useful indicator. Here it is important to note that
the main psychopathological burden across the lifespan
occurs in transitional periods, namely during transition
from childhood to adulthood. In fact, half of the life-
time psychopathological burden can be detected by the
mid-teens and 75% by the mid-20s (Kessler et al., 2007).
Therefore, biomedical research focussing on transitional
periods should have high priority. In addition, most
mental disorders are the result of an interaction of
individual biology and environmental factors. Identiﬁca-
tion and characterisation of environmental factors con-
ferring risk and resilience for mental disorders and their
interaction/correlation with biological mechanisms is
thus also of high priority.
While it is crucial to take into consideration the amount
of psychopathological burden to prioritise gaps and
advances needed it is of equal importance to identify
areas where scientiﬁc progress is most likely to occur in
the future. In recent years there has been a tremendous
advance in basic neuroscience, which took advantage of
new technologies, as well as emerging disciplines, such
as systems biology. This progress has allowed the
identiﬁcation of brain mechanisms, including an increas-
ingly evolved characterisation of individual differences.
However, these advances did not yet induce a compar-
able progress in diagnosis and treatment of mental
disorders. Thus a “translational gap” has emerged which
calls for the application of scientiﬁc and methodical
advances in basic neurosciences to better understand
human diversity and develop diagnostics and interven-
tions that target speciﬁc pathological processes across
mental disorders. Research aiming at decreasing this
“translational gap” should be prioritised.(2) The structural and infrastructural advances needed to
achieve the discovery goals on a European scale include
the creation of sustained transnational collaborative
structures and infrastructures which take into account
the competitive advantages of different European
regions, collaboration with existing institutions, Eur-
opean research infrastructure projects, national cohorts
etc., as well as capacity building across Europe. The
scope of the effort to establish structural and infra-
structural advances is considerable and includes the
establishment of dedicated centres for data acquisition
and data analysis, as well as research networks.
Together dedicated centres and networks may contri-
bute to developing and support a sustained research
infrastructure to maximally beneﬁt from Europe's
unique universal access to healthcare and its cultural
diversity, which allows differentiated analysis ofenvironmental and cultural inﬂuences. This infrastruc-
ture should lead to the creation of a “European Institute
of Mental Health” as a counterpart to the American
National Institute of Mental Health, which in addition to
reducing the personal and public burden of mental
disorders, might be an important partner for pharma-
ceutical industry and strengthen European competive-
ness and advantage of location.The proposed research infrastructure should be adapted
to the regional strengths and needs in the different
countries of the European Community thus beneﬁting from
the competitive advantages of different regions. While the
integration of research groups from the new member states
into European research structures is in progress, their
research potential has not been fully understood and
properly utilised. Whereas there is an educated workforce
and a strong tradition of psychiatric and neuroscience
research in most Eastern European countries, there remains
stigma associated with psychiatric disorders resulting in
disinvestment and regulatory instability in some regions.
This is further complicated by brain drain into Western
European or non-European countries and – with notable
exceptions – limited access to European funds. A successful
integrative strategy will respond to regional needs, for
example by creating and/or improving a basic clinical
research infrastructure and providing measures to counter-
act brain drain in these regions. Conversely, highly devel-
oped regions within the European Community might have
access to worldwide leading academic centres and facil-
ities. Here providing for sustained collaborative ties and
targeted research programmes may improve synergy and
further increase competitiveness. Despite regional differ-
ences, the united Europe should be considered as a “single
space” competing at a global level. Development of a
regionally adapted research infrastructure, including invest-
ment in electronic communication and research technolo-
gies will contribute to preserving Europe's competitiveness
at “big science projects”, for example in genetics, epide-
miology and non-industry funded clinical trials. Further-
more, certain overarching public health issues in Europe (e.
g., alcohol and substance abuse, cognitive and psychiatric
effects of aging) require the old and the new member states
to reach out to one another. Therefore, clear incentives are
needed to promote and strengthen processes and structures
to break down traditional European barriers, and encourage
collaborative research in order to capture local expertise in
the most efﬁcient way.
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